<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mater Today Chem</journal-id><journal-id journal-id-type="iso-abbrev">Mater Today Chem</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>Materials Today. Chemistry</journal-title></journal-title-group><issn pub-type="epub">2468-5194</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9981536</article-id><article-id pub-id-type="pmcid-ver">PMC9981536.1</article-id><article-id pub-id-type="pmcaid">9981536</article-id><article-id pub-id-type="pmcaiid">9981536</article-id><article-id pub-id-type="pmid">36950312</article-id><article-id pub-id-type="doi">10.1016/j.mtchem.2023.101478</article-id><article-id pub-id-type="pii">S2468-5194(23)00105-2</article-id><article-id pub-id-type="publisher-id">101478</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Solanki</surname><given-names initials="R">R.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Shankar</surname><given-names initials="A">A.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Modi</surname><given-names initials="U">U.</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Patel</surname><given-names initials="S">S.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>a</label>School of Life Sciences, Central University of Gujarat, Sector-30, Gandhinagar, 382030, India</aff><aff id="aff2"><label>b</label>Biomaterials &amp; Biomimetics Laboratory, School of Life Sciences, Central University of Gujarat, Sector-30, Gandhinagar, 382030, India</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author.</corresp><fn id="fn1"><label>1</label><p id="ntpara0010">Authors have contributed equally.</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>3</day><month>3</month><year>2023</year></pub-date><volume>29</volume><issue-id pub-id-type="pmc-issue-id">430309</issue-id><fpage>101478</fpage><lpage>101478</lpage><history><date date-type="received"><day>23</day><month>11</month><year>2022</year></date><date date-type="rev-recd"><day>13</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>25</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>03</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-28 05:27:17.843"><day>28</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>The recent outbreak of SARS-CoV-2 resulted into the deadly COVID-19 pandemic, which has made a profound impact on mankind and the world health care system. SARS-CoV-2 is mainly transmitted within the population via symptomatic carriers, enters the host cell via ACE2 and TMPSSR2 receptors and damages the organs. The standard diagnostic tests and treatment methods implemented lack required efficiency to beat SARS-CoV-2 in the race of its spreading. The most prominently used diagnostic test,reverse transcription-polymerase chain reaction (a nucleic acid-based method), has limitations including a prolonged time taken to reveal results, limited sensitivity, a high rate of false negative results, and lacking specificity due to a homology with other viruses. Furthermore, as part of the treatment, antiviral drugs such as remdesivir, favipiravir, lopinavir/ritonavir, chloroquine, daclatasvir, atazanavir, and many more have been tested clinically to check their potency for the treatment of SARS-CoV-2 but none of these antiviral drugs are the definitive cure or suitable prophylaxis. Thus, it is always required to combat SARS-CoV-2 spread and infection for a better and precise prognosis. This review answers the above mentioned challenges by employing nanomedicine for the development of improved detection, treatment, and prevention strategies for SARS-CoV-2. In this review, nanotechnology-based detection methods such as colorimetric assays, photothermal biosensors, molecularly imprinted nanoparticles sensors, electrochemical nanoimmunosensors, aptamer-based biosensors have been discussed. Furthermore, nanotechnology-based treatment strategies involving polymeric nanoparticles, metallic nanoparticles, lipid nanoparticles, and nanocarrier-based antiviral siRNA delivery have been depicted. Moreover, SARS-CoV-2 prevention strategies, which include the nanotechnology for upgrading personal protective equipment, facemasks, ocular protection gears, and nanopolymer-based disinfectants, have been also reviewed. This review will provide a one-site informative platform for researchers to explore the crucial role of nanomedicine in managing the COVID-19 curse more effectively.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1_lrg.jpg"/></fig></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Diagnosis</kwd><kwd>Nanotechnology</kwd><kwd>Prevention</kwd><kwd>SARS-CoV-2</kwd><kwd>Treatment</kwd><kwd>Targeted drug delivery</kwd><kwd>Vaccine delivery</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0040">The current global health threat is the novel coronavirus infection-2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) data suggest that SARS-CoV-2 has resulted in 630 million infections and 65 million deaths (as of November 21, 2022). SARS-CoV-2 belongs to the Coronaviridae family and contains (single stranded RNA) in the beta form. The SARS-CoV-2 infection shows a number of different types of symptoms, such as an asymptomatic condition or symptoms leading to death.</p><p id="p0045">For SARS-CoV-2, no effective antiviral treatment has been found. The treatment of COVID-19 has been carried out on the basis of symptoms and depending on the severity of the illness. However, certain antiviral drugs were reportedly used in the treatment of COVID-19 such as ribavirin, ritonavir, and remdesivir to bring down the viral load and avert further complications [<xref rid="bib1" ref-type="bibr">1</xref>]. Remdesivir was found successful and efficient in the treatment of the very first patient in the United States with a promising outcome [<xref rid="bib2" ref-type="bibr">2</xref>]. However, clinical trials for antiviral drugs to be performed in a randomized controlled form are lagging because of the lengthy procedures required to ensure their safety and efficacy. Although, in accumulated evidence of a report inclusive of 42 patients infected with SARS-CoV-2, 21% were given corticosteroids. Corticosteroids was used for the suppression of lung inflammation [<xref rid="bib3" ref-type="bibr">3</xref>] but later on the utilization of corticosteroids was not accepted, as observed from the clinical outcomes. In an experimental study of critically ill adults of 309, all the patients treated with corticosteroids were vulnerable to take support of mechanical ventilators [<xref rid="bib4" ref-type="bibr">4</xref>]. Vaccine development is a crucial and ultimate treatment of any disease, it not only controls the transmission rate of an ongoing pandemic but also prevents its further spread in the future. However, the administration of a vaccine cannot be completely free from risks or complications. One such drawback is vaccine-associated autoimmunity. In vaccine-associated autoimmunity, the adjuvants or the antigens&#8217; cross-reactions may sometimes be causative factors [<xref rid="bib5" ref-type="bibr">5</xref>]. It is further complicated in patients already battling immune-mediated diseases and could lead to a cascade of immunological responses in the body. Ultimately, the introduction of novel viral strains and/or mutations in the viral genome leaves the conventional treatments ineffective.</p><p id="p0050">The COVID-19 epidemic is projected to extend long beyond 2022, putting even more strain on the world's already overcrowded healthcare system. Exploring methods and treatments based on nanotechnology to tackle COVID-19 will aid in overcoming the limits of traditional viral illness management strategies. As a result, scientists are focusing their efforts on new nanotechnology-based innovations that have the potential to dramatically lessen the stress caused by the COVID-19 pandemic. Exploring and implementing prevention, diagnosis, and therapy based on nanotechnology, a paradigm shift in the battle of COVID-19 vs. mankind war will be very prominent [<xref rid="bib6" ref-type="bibr">6</xref>]. For example, Moderna collaborated with the Vaccine Research Center at the U.S. National Institutes of Health to develop and carry out clinical trials for mRNA-encapsulated in a lipid nanoparticles (LNPs) vaccine [<xref rid="bib7" ref-type="bibr">7</xref>]. Another mRNA-based vaccine was developed by Pfizer-BioNTech, which is Food and Drug Administration (FDA) approved for use in an emergency situation to prevent COVID-19 [<xref rid="bib8" ref-type="bibr">8</xref>]. Both BioNTech/Pfizer and Moderna have been using LNPs for the mRNA vaccine that encode the S protein of SARS-CoV-2. The S protein is the viral protein that interacts with ACE2 on cells to mediate infection. Thus, the S protein is a potential vaccine target because it is considered that antibodies attach to the right epitope on the S protein and may be neutralizing, preventing intercellular viral transmission. These are a few instances of how nanotechnology-based methods have been used to treat SARS-CoV-2. In this review, we reviewed several strategies using nanotechnology to treat SARS-CoV-2 (Section <xref rid="sec3.2" ref-type="sec">3.2</xref>). The present review examines nanomedicine approaches and their potent implementation that could aid in a better management of the COVID-19 pandemic, attributed to the nanoscale structures and their advantages.</p><p id="p0055">Advantages of nanotechnology in SARS-CoV-2 treatment.<list list-type="simple" id="ulist0015"><list-item id="u0035"><label>&#8226;</label><p id="p0060">Increased Bioavailability: nanotechnology enables the delivery of higher concentrations of antiviral drugs and vaccines to specific target sites in the body, resulting in better bioavailability and efficacy.</p></list-item><list-item id="u0040"><label>&#8226;</label><p id="p0065">Reduced Dosing Regimen: nanoparticle-based drug delivery systems can allow for fewer doses of antiviral drugs and vaccines, making treatment more convenient for patients.</p></list-item><list-item id="u0045"><label>&#8226;</label><p id="p0070">Improved Stability: NPs can help protect the drug or vaccine from degradation or oxidation, resulting in a longer shelf life and stability of the therapeutic.</p></list-item><list-item id="u0050"><label>&#8226;</label><p id="p0075">Enhanced specificity: NPs can be engineered to target specific cells or tissues in the body, reducing the risk of off-target effects and increasing the specificity of the treatment.</p></list-item><list-item id="u0055"><label>&#8226;</label><p id="p0080">Improved Safety Profile: NPs can help reduce the toxicity of antiviral drugs and vaccines by allowing for targeted delivery and reducing the amount of the active ingredient required.</p></list-item><list-item id="u0060"><label>&#8226;</label><p id="p0085">Improved Ease of Administration: NPs -based drug delivery systems can be designed for a non-invasive administration, such as oral or topical, improving the ease of administration for patients.</p></list-item><list-item id="u0065"><label>&#8226;</label><p id="p0090">Increased Patient Compliance: NPs -based drug delivery systems can reduce the need for frequent dosing and improve the overall convenience and safety of treatment, increasing patient compliance.</p></list-item><list-item id="u0070"><label>&#8226;</label><p id="p0095">Enhanced Immune Response: NPs can be engineered to stimulate an immune response, resulting in more effective antiviral vaccines and improved overall treatment outcomes.</p></list-item></list>
</p><p id="p0100">In this article, we have analyzed nanotechnology-based antiviral strategies and explored how they are being developed to tackle SARS-CoV-2 from three perspectives. First, we have reviewed the designs of NPs that can be used to quickly, accurately, and conveniently detect the SARS-CoV-2 virus. Second, we have examined NP designs that use host mimicry to either enhance the activity of already-existing antiviral agents or develop wholly new antiviral mechanisms. In the third section, we have gone through SARS-CoV-2 prevention strategies using NPs. Researchers would be benefitted from the nanotechnology-based methodologies discussed in this study and aid in generating novel COVID-19 diagnostic and treatment modalities.</p></sec><sec id="sec2"><label>2</label><title>SARS-CoV-2: an overview</title><sec id="sec2.1"><label>2.1</label><title>Origin, morphology, structure, and genomic organization</title><p id="p0105">The origin of the disease remains a puzzle and debatable. There are no clear explanations as to how it emerged in the human population. Human coronaviruses first appeared in the literature, in the mid-1960s, isolated by Tyrrell and Bynoe, who were experimenting with human strains and many animal viruses [<xref rid="bib9" ref-type="bibr">9</xref>]. The coronavirus was first discovered in the cultures isolated from the human embryonic trachea taken from the respiratory tract of an adult having a common cold. The virus's name is derived from its crown-like (&#8220;<italic toggle="yes">corona</italic>&#8221; in Latin) morphological appearance of coronaviruses established by Almeida and Tyrrell [<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib11" ref-type="bibr">11</xref>].</p><p id="p0110">In December 2019, in Wuhan, China, multiple pneumonia cases emerged. The WHO first assigned the name of the causative virus as the 2019-novel coronavirus (2019-nCoV). However, later its nomenclature was changed to SARS-CoV-2 by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses. Through the research conducted, the SARS CoV-2 basic reproduction number (R0) came to be around 2.2 according to the evaluation report [<xref rid="bib12" ref-type="bibr">12</xref>]. After several pneumonia cases emerged in Wuhan, SARS-CoV-2 was promptly isolated from the patient in a very short period by the scientists in China and initiated its genome sequencing. According to the research, the SARS-CoV-2 genome sequence has a 79.5% match with SARS-CoV-1. Furthermore, it showed a 96% genome similarity with RaTG13, a bat coronavirus [<xref rid="bib13" ref-type="bibr">13</xref>]. Thus, on the basis of evolutionary studies and genome similarity, the bat has been considered the foremost suspect as a prime biological host of SARS-CoV-2.</p><p id="p0115">Thorough research of the viral protein structure and its impact on its functionality while interacting with the host machinery is necessary to understand to combat the virus. It exists usually in a spherical shape and in a nanoscale diameter; however, a larger pleomorphic particulate shape is also prevalent. Studies were conducted to examine the SARS-CoV-2 structure utilizing the transmission electron microscope (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>
A) [<xref rid="bib14" ref-type="bibr">14</xref>].<fig id="fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>SARS-CoV-2 structure examined under the transmission electron microscope (A) (Figure&#160;adopted from Ref.&#160;[<xref rid="bib14" ref-type="bibr">14</xref>]). A schematic diagram of the structural proteins of SARS-CoV-2 (B). Genomic organization of SARS-CoV-2 (C) (Figure&#160;adopted from Ref.&#160;[<xref rid="bib13" ref-type="bibr">13</xref>]).</p></caption><alt-text id="alttext0010">Fig.&#160;1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p><p id="p0120">The examination of SARS-CoV-2 deciphered the structure alike the other coronaviruses, wherein the virus size ranged from 70 to 90&#160;nm [<xref rid="bib13" ref-type="bibr">13</xref>]. Coronaviruses are single stranded RNAviruses belonging to the <italic toggle="yes">Coronaviridae</italic> family [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib16" ref-type="bibr">16</xref>]. The SARS-CoV-2 structural proteins consist of a nucleocapsid protein (N), a small envelope protein (E), a matrix protein (M), and a spike surface glycoprotein (S) (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>B). The helical nucleocapsid is surrounded by the envelope. Further, it is encircled by the membrane and the spike protein (S). These three proteins mainly get incorporated into the host membrane lipid bilayer [<xref rid="bib17" ref-type="bibr">17</xref>].</p><p id="p0125">The coronavirus genome consists of 9,680 amino acid polyproteins, coding 6 to 11 open reading frames (ORFs) approximately 26&#8211;32&#160;kb (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>C) [<xref rid="bib12" ref-type="bibr">12</xref>]. The first ORF, which encodes 16 non-structural proteins (NSPs), makes up roughly 67% of the genome, while the other ORFs code for the other structural proteins [<xref rid="bib13" ref-type="bibr">13</xref>]. Most of the encoded proteins of SARS-CoV-2 match to that of the known SARS-CoV-2. Several studies have attempted to conclude that the mutation in NSP2 and NSP3 is responsible for its infectious capability and helps in various differentiation mechanisms of SARS-CoV-2 [<xref rid="bib12" ref-type="bibr">12</xref>].</p></sec><sec id="sec2.2"><label>2.2</label><title>Pathophysiology, mode of spread, and symptoms</title><p id="p0130">We know that angiotensin-converting enzyme 2 is the highly expressed functional receptor in the human lungs. This makes it the primary site of infection. Hence, the common symptoms of COVID-19 are related to respiration and can be mild to the severe respiratory uneasiness that the patient may require hospitalization (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref>
).<fig id="fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>A schematic representation of the mode of spread of COVID-19.</p></caption><alt-text id="alttext0015">Fig.&#160;2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2_lrg.jpg"/></fig></p><p id="p0135">SARS-CoV-2 is mainly transmitted from one human to another. It is majorly spread by coughing and sneezing. Moreover, the virus particles were identified in aerosols at infectious concentrations for up to 3&#160;h or even long-lasting. Further, there is evidence that suggests that it is transmitted via aerosols [<xref rid="bib19" ref-type="bibr">18</xref>].</p><p id="p0140">Direct contact with infected patients is another mode of transmission. Fomite transmission is also been reported for these viral particles due to their capability of remaining for a period of time on the surfaces, depending on the surface material [<xref rid="bib20" ref-type="bibr">19</xref>]. Other means of transmission include sexual intercourse, according to recent data, oral-fecal transmission might also be possible (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref>
) [<xref rid="bib21" ref-type="bibr">20</xref>]. Given the thoroughly studied evidence, vertical transmission of COVID-19 is also possible. The standard and conventional methods for detecting COVID-19 infection are the identification of the viral RNA through reverse transcription-polymerase chain reaction (RT-PCR). The presence of COVID-19 viral RNA-positive serology was also noted in several fetal or neonatal sources [<xref rid="bib22" ref-type="bibr">21</xref>].<fig id="fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>A schematic representation of the SARS-CoV-2 mode of entry and its replication (Figure&#160;adopted from Ref.&#160;[<xref rid="bib25" ref-type="bibr">22</xref>]).</p></caption><alt-text id="alttext0020">Fig.&#160;3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3_lrg.jpg"/></fig></p><p id="p0145">COVID-19 gradually became a pandemic as it has a broad spectrum of manifestations. Majorly, the SAR-CoV-2-positive cases reported had mild indications of the disease or showed no symptoms at all. The classic symptoms of COVID-19 include breathlessness, cold, and cough, with subsequent fundamental other symptoms such as fever, fatigue, and body ache [<xref rid="bib3" ref-type="bibr">3</xref>]. Out of these, the most prevailing symptom in 98% of the symptomatic cases is fever. Additional symptoms are pharyngitis, i.e. pain or scratchiness in the throat, loss of smell and taste, head and muscle aches, chills, and tremors. The virus takes 14 days to incubate in the human body followed by infection, and symptoms often appear 3&#8211;7 days afterward.</p></sec><sec id="sec2.3"><label>2.3</label><title>COVID-19 diagnostic methods and conventional treatments</title><p id="p0150">To avert COVID-19 from fast spreading, it was crucial to implement rapid diagnostic methods. The RNA-based PCR and SARS-CoV-2 antigen tests were approved by the FDA to diagnose the COVID-19 infection. Further, according to the Indian Council of Medical Research, 162 antigen-based rapid test kits have been validated to date [<xref rid="bib28" ref-type="bibr">23</xref>].</p><sec id="sec2.3.1"><label>2.3.1</label><title>PCR</title><p id="p0155">Antigen tests are less expensive and able to give results immediately compared to PCR tests. But PCR tests give more accurate results than antigen tests. Therefore, doctors may recommend a PCR test for further confirmation. At present, the most widely utilized diagnostic test is PCR. Samples can be extracted from swabs taken from the oropharyngeal and nasopharyngeal regions. Also, sputum, stool, saliva, and fluid derived from the lower respiratory tract and blood are implied as the sample as well.</p></sec><sec id="sec2.3.2"><label>2.3.2</label><title>X-ray</title><p id="p0160">The most conventional diagnostic method for detecting lung infections is a chest X-ray, which is estimated to be around 69% sensitive in the case of patients with positive results [<xref rid="bib29" ref-type="bibr">24</xref>]. Also, the chest X-ray can be negative in 25% of cases too [<xref rid="bib30" ref-type="bibr">25</xref>].</p></sec><sec id="sec2.3.3"><label>2.3.3</label><title>RT-PCR</title><p id="p0165">Furthermore, the SARS-CoV-2-positive nucleic acid presence can be diagnosed by utilizing fluorescence probe-based real-time RT-PCR. However, this diagnostic method gets influenced by various environmental factors such as specimen sampling, handling while processing the procedure, and the detection reagents used. As a result, most of the cases show errors in reports or false positive results. Also, the period to conclude the result is too lengthy. Three issues are majorly faced with the RT-PCR method for diagnosis [<xref rid="bib31" ref-type="bibr">26</xref>,<xref rid="bib32" ref-type="bibr">27</xref>]: first, due to the increased demand for PCR reagent kits during excessive testing, the supplies don't match adequate standards. Second, high-sampling specimens are not manageable by the rural community hospitals and they lack the needed infrastructure for carrying out the procedure and running PCR. Third, the RT-PCR result depends on the presence of SARS-CoV-2 detection in the particular sample and the sampling time point taken, i.e. when a person who was asymptomatic in the beginning and is now on the verge of recovery takes a PCR test, his/her prior infection would not be identified and thereby adequate control measures would not be taken on time [<xref rid="bib33" ref-type="bibr">28</xref>].</p></sec><sec id="sec2.3.4"><label>2.3.4</label><title>Computer tomography</title><p id="p0170">A computer tomography scan is an alternative method that uses the principle of imaging for diagnosing and conducting clinical check-ups of COVID-19 patients. Computer tomography scans are not affordable for the majority of patients, their handling is complex and therefore demands good experience and high technical expertise, and it fails to safely diagnose COVID-19. Hence, other techniques need to be taken into consideration to address these shortcomings for the COVID-19 diagnosis.</p></sec><sec id="sec2.3.5"><label>2.3.5</label><title>Antiviral drugs/vaccines</title><p id="p0175">COVID-19 treatment depends on its severity. For a less severe condition, the patient can be treated at home by resting and taking medicine to reduce fever. Antiviral tablets such as Favipiravir, earlier known as T-705, might be taken orally. It halts the replication of viral RNA by inhibiting the RNA polymerase. The dose of the antiviral depends on the type of the infection severity. The more severe cases require hospitalization with treatment that includes intravenous antivirals such as remdesivir (received the approval from FDA for hospitalized patients' treatment in October 2020) and corticosteroids. Moreover, supplemental oxygen-assisted ventilation and other invasive or non-invasive treatments were supplemented in the hospitals to the COVID-19 patients to support their recovery and aid to fight the infection. The use of blood plasma of a person previously infected with COVID-19 is another potential therapy that comes under conventional treatment which supplements patients&#8217; immune systems. Multiple efforts are currently ongoing to control and treat COVID-19.</p><p id="p0180">According to infection severity, the monoclonal antibodies for enhanced targeted drug treatment, as effective as an antiviral against most of the COVID-19 causing viral strains, broad-spectrum antibiotics, and various supplementary vitamins are recommended to treat COVID-19. Cannabidiol, Zinc supplements, Vitamin-D, Ivermectin (Ivermectin), Vitamin-C, and Doxycycline combinations have been used for boosting the immunity of the patients and lessening the severity. Several COVID-19 vaccines have been approved worldwide. A vaccine elicits the body's adaptive immune system by mimicking a particular pathogen, exposing its specific antigens, and later when the actual infection happens, the body's immune system reacts strongly against it [<xref rid="bib35" ref-type="bibr">29</xref>].</p><p id="p0185">Various companies produced a wide array of vaccines against the viral strains causing COVID-19. Pfizer-BioNTech and Moderna companies came up mRNA-based vaccines with 94&#8211;95% effectiveness against SARS-CoV-2. A recombinant ChAdOx1 nCoV-19 Corona virus vaccine is manufactured by AstraZeneca and the University of Oxford, a joint venture. It is a chimpanzee adenovirus vector that is replication-deficient and encodes for the spike (S) glycoprotein of the SARS-CoV-2. Another recombinant COVID vaccine named COVISHIELD&#8482; was developed by the Serum Institute of India Pvt. Ltd [<xref rid="bib36" ref-type="bibr">30</xref>]. The efficiency of the vaccine was studied thoroughly in several countries like the UK, Brazil, and South Africa [<xref rid="bib37" ref-type="bibr">31</xref>]. Recently, the WHO authorized the use of ChAdOx1-S, which was jointly developed by the Serum Institute, India, and AstraZeneca-SKBio (the Republic of Korea). It is also a vector-based vaccine and has 63.09% efficacy [<xref rid="bib35" ref-type="bibr">29</xref>]. In India, Bharat Biotech collaborated with the Indian Council of Medical Research, National Institute of Virology, and developed India's first indigenous vaccine, COVAXIN&#174;, to combat COVID-19 [<xref rid="bib38" ref-type="bibr">32</xref>]. It has been developed as an inactivated vaccine using &#8216;Whole Virion Inactivated Vero Cell Technology&#8217; with the vaccine adjuvant to boost immunogenicity. Another vaccine named as Sinopharm Beijing (BBIBP-CorV), developed by the Beijing Institute of Biological Products Co., Ltd has shown the efficacy of 79% against symptomatic SARS-CoV-2 infection of 14 days or more after the second dose and hospitalized patients [<xref rid="bib39" ref-type="bibr">33</xref>]. On April 16, 2020, Beijing Kexing Zhongwei Biotechnology Co., Ltd. (sinovac), a division of Kexing Biology, began the phase I/II clinical study of the Coronavirus inactivated vaccine, which was made available on June 13, 2020 [<xref rid="bib40" ref-type="bibr">34</xref>]. The findings indicated that more than 90% of neutralizing antibodies tested positively. Additionally, the precise findings of the phase III clinical trials carried out by Brazilian medical professionals revealed that two doses of the Sinovac Coronavirus vaccine provided 100% protection for moderate and severe cases of COVID-19 and 50.7% protection for symptomatic individuals. The adenovirus vector vaccine: type 5 adenovirus vector vaccine (Ad5-nCoV vaccine) produced by Tianjin Kangxinuo Company is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies [<xref rid="bib41" ref-type="bibr">35</xref>]. In the phase 3 clinical trial, the observed results suggested that the Ad5-nCoV vaccine was highly effective against serious infection and protected against laboratory-confirmed symptomatic COVID-19. The FDA provisionally approved the recombinant new coronavirus protein vaccine (CHO cells) developed by Anhui zhifeilong Kema biopharmaceutical Co., Ltd. on March 1st [<xref rid="bib42" ref-type="bibr">36</xref>]. According to the State Food and Drug Administration's official website, it is the first domestic recombinant novel coronavirus protein vaccine that has been authorized and is useful for preventing diseases caused by the novel coronavirus infection (COVID-19). Following vaccines are considered to be effective against emerging new COVID-19 variants, however, there are certain adverse side effects experienced following vaccine immunization such as pain due to inflammation at the injected site, muscle pain, and fever [<xref rid="bib43" ref-type="bibr">37</xref>]. The vaccines manufactured do not have 100% efficiency and hence chances of re-infection exist even after vaccination. Moreover, an efficient strategy is required for determining the accurate rate of vaccine production to meet the high demand to fulfill vaccination covering the maximum population within a short period [<xref rid="bib44" ref-type="bibr">38</xref>]. There are several limitations to the process of vaccination. Although mRNA vaccines are considered to be one of the safest vaccines, as it shows no risk of genomic integration, mRNA/DNA vaccines work as continuous antigen-generating machinery. Thus, it may not trigger the desired immune response in the host's body at the optimum level needed. It may even cause immunogenic effects and as a result, lead to T-cell exhaustion [<xref rid="bib45" ref-type="bibr">39</xref>]. Other than this drawback, additionally nucleic acid-based vaccines trigger type I interferon production in response to the vaccine-associated inflammation that may lead to the development of an autoimmune disease [<xref rid="bib46" ref-type="bibr">40</xref>]. A better understanding of these prophylactic agents and overcoming their drawbacks using alternative approaches and technologies are required to combat the COVID-19 pandemic more safely and efficiently.</p><p id="p0190">One way to conquer these shortcomings and build an effective treatment against the viral infection is to adopt a multidisciplinary approach. This motivates scientists to explore the field of nanotechnology, which has recently gained popularity and is being positively scrutinized for its potential utilization in combating viral infections by including its usage in developing preventive treatment [<xref rid="bib47" ref-type="bibr">41</xref>,<xref rid="bib48" ref-type="bibr">42</xref>]. NPs provide distinctive physical properties that have been majorly elucidated for their advantages in drug delivery technology. The efficient coordination between nanostructures and microorganisms is transforming the biomedical field at a fast pace and is considered to be the potent ideal solution so far. The recent advances in nanomedicine have led to the advantages such as targeted drug delivery, biocompatibility, and its potential to procure slow, sustained, and targeted drug release, which offers the upper hand to overcome challenges linked with the conventional drug-related treatments and therapies [<xref rid="bib49" ref-type="bibr">43</xref>].</p></sec></sec></sec><sec id="sec3"><label>3</label><title>SARS-CoV-2 therapeutic strategies: a nanomedicine-based approach</title><p id="p0195">Nanotechnology is the field dealing with the study and application of materials having a diameter of fewer than 100&#160;nm [<xref rid="bib50" ref-type="bibr">[44]</xref>, <xref rid="bib51" ref-type="bibr">[45]</xref>, <xref rid="bib52" ref-type="bibr">[46]</xref>]. Nanotechnology applications can be found in a variety of domains, including biomedicine, material engineering, chemistry, physics, engineering, and computer engineering [<xref rid="bib53" ref-type="bibr">47</xref>]. Recently, nanotechnology has bloomed in the field of biological sciences as it has potently aided advancement in the aspects of advancing new diagnostics and therapeutics. The application of nanotechnology is widely desired in the field of medical sciences due to its special qualities, such as providing more surface area to a volume ratio due to its nanoscale size, aiding multifunctionality, improved solubility, and surface adaptability. These qualities aid in developing targeted therapies, efficient novel drug candidates, early diagnostic tools, and patient personalized medicines, which will be safer and more effective than the existing options. The potential of nanotechnology is undeniable in the present COVID-19 pandemic scenario. The following are some of the benefits of nanomaterials in antiviral studies.<list list-type="simple" id="ulist0020"><list-item id="u0075"><label>&#8226;</label><p id="p0200">Aids in the administration of water-insoluble pharmaceuticals [<xref rid="bib54" ref-type="bibr">48</xref>,<xref rid="bib55" ref-type="bibr">49</xref>].</p></list-item><list-item id="u0080"><label>&#8226;</label><p id="p0205">Increases the circulation of medicines to circulate in the body [<xref rid="bib56" ref-type="bibr">[50]</xref>, <xref rid="bib57" ref-type="bibr">[51]</xref>, <xref rid="bib58" ref-type="bibr">[52]</xref>].</p></list-item><list-item id="u0085"><label>&#8226;</label><p id="p0210">It is possible to improve drug efficiency and reduce side effects [<xref rid="bib59" ref-type="bibr">[53]</xref>, <xref rid="bib60" ref-type="bibr">[54]</xref>, <xref rid="bib61" ref-type="bibr">[55]</xref>].</p></list-item><list-item id="u0090"><label>&#8226;</label><p id="p0215">By protecting DNA and mRNA vaccines, it overcomes obstacles for <italic toggle="yes">in&#160;vivo</italic> applications [<xref rid="bib62" ref-type="bibr">56</xref>,<xref rid="bib63" ref-type="bibr">57</xref>].</p></list-item><list-item id="u0095"><label>&#8226;</label><p id="p0220">Capacity to carry multiple drugs/vaccines simultaneously [<xref rid="bib64" ref-type="bibr">[58]</xref>, <xref rid="bib65" ref-type="bibr">[59]</xref>, <xref rid="bib66" ref-type="bibr">[60]</xref>].</p></list-item></list>
</p><p id="p0225">Despite our growing understanding of antiviral strategies and the similarities between SARS-CoV-2 and other viruses, the present medications for COVID-19 therapeutics are inefficient and have side effects. Nanotechnology-based strategies can be utilized in a variety of ways to combat COVID-19, including prevention, diagnosis, and treatment (<xref rid="fig4" ref-type="fig">Fig.&#160;4</xref>
).<fig id="fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>A schematic representation of the nano-medicinal approaches for SARS-CoV-2 diagnosis, treatment, and prevention.</p></caption><alt-text id="alttext0025">Fig.&#160;4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4_lrg.jpg"/></fig></p><p id="p0230">In this section, we have explored that the nanotechnology-based approaches for the diagnosis of SARS-CoV-2 aim to take less time for detection and aiding a simple approach. Additionally, an approach for the development of targeted nano-drug delivery systems for anti-viral therapeutics was discussed. Furthermore, we have explored nano-formulations that aim to ameliorate the efficiency of the present antiviral drugs. In the end of the section, novel nanomaterials used in the prevention of SARS-CoV-2 was discussed.</p><sec id="sec3.1"><label>3.1</label><title>SARS-CoV-2 diagnostic strategies: a nanotechnology-based approach</title><p id="p0235">Infectious COVID-19 outbreaks around the world demand the development of quick and effective diagnostic technologies. Nucleic acid detection-based tests through RT-PCR have several drawbacks, including high instances of false results, lack of sensitivity, time taking process to reach the results, and limited specificity due to genetic homology with other viruses [<xref rid="bib67" ref-type="bibr">61</xref>]. Furthermore, rural healthcare facilities lack the essential PCR infrastructure to handle huge sample volumes, and the availability of sufficient RT-PCR reagents and kits is not enough to suffice the growing demand during the COID-19 pandemic [<xref rid="bib68" ref-type="bibr">62</xref>]. A precise diagnosis of COVID-19 is crucial to improve the patients&#8217; prognosis. Thus, the generation of sensitive nucleic acid or protein-based point-of-care diagnostic tools to test SARS-CoV-2 more specifically is urgently in demand. Various nanomaterials are used for SARS-CoV-2 identification including metal NPs , polymeric NPs , dendrimers, etc. These NPs are frequently described as being suited for a wide range of biosensing activities and biomedical applications, where the NPs would interact with RNA, DNA, or antibodies mainly for identifying viruses [<xref rid="bib69" ref-type="bibr">63</xref>,<xref rid="bib70" ref-type="bibr">64</xref>]. Additionally, in point-of-care devices too, NPs have been utilized due to their advantages such as their nano-feature size, aid in precise sensing, infer chemical stability, excellent electrical conductivity, and the localized surface plasmon resonanceeffect) [<xref rid="bib71" ref-type="bibr">[65]</xref>, <xref rid="bib72" ref-type="bibr">[66]</xref>, <xref rid="bib73" ref-type="bibr">[67]</xref>]. The introduction of NPs in analytical equipment could improve detection systems' sensitivity and specificity. Several nanomaterials detection platforms have been generated for quick and precise SARS-CoV detection. Colorimetric assays based on NPs [<xref rid="bib74" ref-type="bibr">68</xref>,<xref rid="bib75" ref-type="bibr">69</xref>], optical sensors [<xref rid="bib76" ref-type="bibr">70</xref>,<xref rid="bib77" ref-type="bibr">71</xref>], nano immunosensors [<xref rid="bib78" ref-type="bibr">72</xref>,<xref rid="bib79" ref-type="bibr">73</xref>], immunochromatographic assays [<xref rid="bib80" ref-type="bibr">74</xref>], aptamer-based assays [<xref rid="bib81" ref-type="bibr">75</xref>], and bio-barcode assays (BCAs) [<xref rid="bib82" ref-type="bibr">[76]</xref>, <xref rid="bib83" ref-type="bibr">[77]</xref>, <xref rid="bib84" ref-type="bibr">[78]</xref>, <xref rid="bib85" ref-type="bibr">[79]</xref>] are some of the nanotechnology-based assays that emerged for SARS-CoV-2 identification and diagnosis.</p><sec id="sec3.1.1"><label>3.1.1</label><title>Colorimetric assays</title><p id="p0240">Colorimetric assays are a common technique to quantify the analytes, where the absorbance measured at a particular wavelength of the color produced by the indicators like nanosized metallic particles and dye molecules is directly proportional to the analytes&#8217; concentration [<xref rid="bib86" ref-type="bibr">80</xref>]. Based on this principle, Hanbi Kim et&#160;al. proposed a simple, fast, and low-cost effective assay for identifying infectious disease (i.e. MERS) colorimetrically [<xref rid="bib86" ref-type="bibr">80</xref>]. The technology developed to colorimetrically detect analyte-included modification of using the metallic NPs has been represented (<xref rid="fig5" ref-type="fig">Fig.&#160;5</xref>
). The NP-based assay aids in the detection of MERS-CoV, implying the detection range up to 1&#160;pmol/L, signifying its sensitivity of identifying the target at low concentration.<fig id="fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Development of a label-free colorimetric assay using gold nanoparticles (Figure&#160;adopted from ACS Sensors [<xref rid="bib86" ref-type="bibr">80</xref>]).</p></caption><alt-text id="alttext0030">Fig.&#160;5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5_lrg.jpg"/></fig></p><p id="p0245">More recently, Tae Jung Park et&#160;al. developed a simple gold binding polypeptides protein approach for the microscale-to nanoscale-controlled immobilization of proteins on a bare gold surface with high selectivity and specificity [<xref rid="bib87" ref-type="bibr">81</xref>]. By aiding the interaction between two proteins (gold binding polypeptides -fusion proteins) with the help of gold NPs (AuNPs), the detection of an analyte colorimetrically became possible. The binding of the SARS-CoV- E protein to the green fluorescent protein (GFP) mounted on AuNPs leads to considerable alters in the absorbance reading in comparison to the color derived during the GFP- AuNP interaction with a complementary antibody. This enables SARS-CoV quantitative identification.</p><p id="p0250">Furthermore, P. Moitra et&#160;al. worked on AuNPs to generate a SARS-CoV-2 detection technology by identifying SARS-CoV-2 RNA. They utilized the complementary binding principle where the NPs were coated with the SARS-CoV-2 N-gene specific antisense oligonucleotides (ASOs), which were in turn thiol modified. The antisense oligonucleotides will complementarily bind the target RNA [<xref rid="bib88" ref-type="bibr">82</xref>]. This colorimetric assay based on the AuNPs&#8217; anisotropic plasmonic features enables targeted binding, bestowing the assay the desired specificity to detect SARS-CoV-2 (<xref rid="fig6" ref-type="fig">Fig.&#160;6</xref>
).<fig id="fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>A schematic illustration of antisense oligonucleotide-capped gold nanoparticles) to detect SARS-CoV-2 RNA (Figure&#160;adopted from ACS Nano [<xref rid="bib88" ref-type="bibr">82</xref>]).</p></caption><alt-text id="alttext0035">Fig.&#160;6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6_lrg.jpg"/></fig></p></sec><sec id="sec3.1.2"><label>3.1.2</label><title>Photothermal biosensor</title><p id="p0255">Guangyu Qiu et&#160;al. worked to design a photothermal biosensor with dual-functional plasmonics. It amalgamates the localized surface plasmon resonance and plasmonic photo thermal technologies for sensing to provide a potent approach for the SARS-CoV-2 diagnosis clinically [<xref rid="bib77" ref-type="bibr">71</xref>]. The developed biosensor has high sensitivity and selectivity towards the SARS-CoV-2 gene sequences and aids in detection capacity at low concentrations, as low as 0.22 pM. Thus, SARS-CoV-2 nano-sensors precision with such technology provides specific identification of the target gene within the multigene pool.</p></sec><sec id="sec3.1.3"><label>3.1.3</label><title>Molecularly imprinted nanoparticles (NanoMIP) sensors</title><p id="p0260">Recently, Jake McClements et&#160;al. synthesized molecularly imprinted nanoparticles (NanoMIP) sensors using a short fragment of SARS-CoV-2 [<xref rid="bib89" ref-type="bibr">83</xref>]. Over antibody-based assays, NanoMIP sensors provide a significant advantage. It efficiently works in challenging media too over the range. To quantitatively detect the SARS-CoV-2 antigen, a thermal test was designed where screen-printed electrodes were utilized, on which NanoMIPS were electrographted. This heat transfer-based setup detected both Alpha and Delta strains&#8217; spike proteins at a very limit of 9.9&#160;fg/mL and 6.1&#160;fg/mL, respectively. This NanoMIP-based detection technique proved to be more sensitive than the antigen test kits available commercially and the other reported antigen assays as well. An assay that can validate the clinical patient&#8217;s samples fast (15&#160;min) with great specificity at the comparatively lowest limit is been generated [<xref rid="bib90" ref-type="bibr">84</xref>].</p></sec><sec id="sec3.1.4"><label>3.1.4</label><title>Electrochemical nano-immunosensors</title><p id="p0265">Apart from colorimetric assays, nano-immunosensors are also nowadays synthesized to detect SARS-CoV-2. Nano-immunosensors are highly sensitive, cost-effective, and capable to be miniaturized. Recently, Laila Ali Layqah and Shimaa Eissa developed a nano-immunosensor, where in a sample, the free virus and MERS-CoV immobilized protein indirectly compete to bind the known, given antibody concentration in the test [<xref rid="bib91" ref-type="bibr">85</xref>]. This approach is extremely precise, sensitive, and selective, with the ability to detect HCoV (0.4&#160;pg/mL) and MERS-CoV (1.0&#160;pg/mL) [<xref rid="bib91" ref-type="bibr">85</xref>].</p><p id="p0270">Additionally, Giwan Seo et&#160;al. reported a SARS-CoV-2 identifying biosensor as well [<xref rid="bib92" ref-type="bibr">86</xref>]. This biosensor utilized SARS-CoV-2 spike protein-specific antibodies, which were coated on the graphene sheets present in the field-effect transistor. This provided the sensor an ability to detect the spike protein of SARS-CoV-2 at 1&#160;fg/mL and 100&#160;fg/mL in phosphate-buffered saline and clinical transport medium, respectively. This sensor successfully identified 2.42&#160;&#215;&#160;10<sup>2</sup> SARS-CoV-2 copies/mL clinically from 19 patients and 1.6&#160;&#215;&#160;10<sup>1</sup>&#160;pfu/mL in a culture medium [<xref rid="bib92" ref-type="bibr">86</xref>].</p></sec><sec id="sec3.1.5"><label>3.1.5</label><title>Aptamer based biosensors</title><p id="p0275">Aptamers are oligonucleotides that can bind specific targets including proteins, peptides, carbohydrates, small molecules, etc., and hence is used as a special class of molecules for a molecular diagnostic and therapeutic purpose [<xref rid="bib93" ref-type="bibr">87</xref>,<xref rid="bib94" ref-type="bibr">88</xref>]. Aptamers are advantageous as a recognition molecule, acting as a chemical equivalent of the antibodies as well, the aptamers allow more sensitivity in comparison with the enzyme or antibodies; thus, being preferred for the development of vast arrays of aptamer-based biosensors [<xref rid="bib95" ref-type="bibr">89</xref>]. The conjugation of the RNA aptamer with the quantum dots and its utilization for rapid and sensitive quantification of the SARS-CoV-2 N protein were demonstrated by Changhyun Roh and Sung Kee Jo at a very less concentration of 0.1&#160;pg/mL [<xref rid="bib81" ref-type="bibr">75</xref>].</p></sec><sec id="sec3.1.6"><label>3.1.6</label><title>Other biosensors</title><p id="p0280">Colloidal gold-immunochromatographic assay and enzyme-linked immunoassay were also reported to identify SARS-CoV-2 [<xref rid="bib96" ref-type="bibr">90</xref>]. With the expeditious nanotechnology development, the BCA has been increasingly utilized for the identification and quantification of a nucleic acid and protein, and target molecules as well as a small molecule, advancing as a new diagnostic tool. The BCA benefits include excellent reproducibility, sensitivity, quick detection time, uncomplicated operation, minimal cost, and a positive association between detection findings [<xref rid="bib97" ref-type="bibr">91</xref>,<xref rid="bib98" ref-type="bibr">92</xref>]. The available literature also suggested that using a NPs -based BCA is one of the most potentially practical approaches for SARS-CoV-2 diagnosis [<xref rid="bib98" ref-type="bibr">[92]</xref>, <xref rid="bib99" ref-type="bibr">[93]</xref>, <xref rid="bib100" ref-type="bibr">[94]</xref>]. Different nanotechnology-based detection approaches for the SARS-Cov-2 virus and other related viruses have been listed out in <xref rid="tbl1" ref-type="table">Table&#160;1</xref>
.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table&#160;1</label><caption><p>Nano-based detection strategies for SARS-Cov-2 and related viruses.</p></caption><alt-text id="alttext0065">Table&#160;1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sr. No.</th><th colspan="1" rowspan="1">Nanomaterial</th><th colspan="1" rowspan="1">Virus</th><th colspan="1" rowspan="1">Detection method</th><th colspan="1" rowspan="1">Limit of detection</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Molecularly imprinted nanoparticles</td><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">NanoMIP-based</td><td colspan="1" rowspan="1">9.9&#160;fg/mL<break/>6.1&#160;fg/mL</td><td colspan="1" rowspan="1">[<xref rid="bib89" ref-type="bibr">83</xref>]</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Thiol-modified probes conjugated to metallic nanoparticles (Gold)</td><td colspan="1" rowspan="1">MERS-CoV-2</td><td colspan="1" rowspan="1">Colorimetric</td><td colspan="1" rowspan="1">1&#160;pmol/&#956;l</td><td colspan="1" rowspan="1">[<xref rid="bib86" ref-type="bibr">80</xref>]</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Gold nanoparticles</td><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Gold binding polypeptides protein approach</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">[<xref rid="bib87" ref-type="bibr">81</xref>]</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Gold nanoparticles functionalized with thiol-modified antisense oligonucleotides</td><td colspan="1" rowspan="1">SARS-CoV-2 N gene</td><td colspan="1" rowspan="1">Colorimetric</td><td colspan="1" rowspan="1">0.18&#160;ng/&#956;l</td><td colspan="1" rowspan="1">[<xref rid="bib88" ref-type="bibr">82</xref>]</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">Gold nanoparticles functionalized with a nucleic acid</td><td colspan="1" rowspan="1">MERS-CoV DNA</td><td colspan="1" rowspan="1">Colorimetric</td><td colspan="1" rowspan="1">1.53&#160;nM</td><td colspan="1" rowspan="1">[<xref rid="bib101" ref-type="bibr">95</xref>]</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Photothermal biosensor</td><td colspan="1" rowspan="1">0.22 pM</td><td colspan="1" rowspan="1">[<xref rid="bib77" ref-type="bibr">71</xref>]</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">Gold nanoparticles functionalized with a carbon electrode</td><td colspan="1" rowspan="1">HCoV<break/>MERS-CoV</td><td colspan="1" rowspan="1">Electrochemical nano-immunosensor</td><td colspan="1" rowspan="1">0.4&#160;pg/mL<break/>1.0&#160;pg/mL</td><td colspan="1" rowspan="1">[<xref rid="bib91" ref-type="bibr">85</xref>]</td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">Thiolated oligonucleotides self-assembled onto gold nanostructured screen-printed carbon electrodes</td><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Electrochemical</td><td colspan="1" rowspan="1">2.5&#160;pmoL/l</td><td colspan="1" rowspan="1">[<xref rid="bib102" ref-type="bibr">96</xref>]</td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">Graphene sheets of a field-effect transistor</td><td colspan="1" rowspan="1">SARS-CoV-2 spike protein</td><td colspan="1" rowspan="1">Electrochemical</td><td colspan="1" rowspan="1">2.42&#160;&#215;&#160;102 SARS-CoV-2 copies/mL clinically</td><td colspan="1" rowspan="1">[<xref rid="bib92" ref-type="bibr">86</xref>]</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">RNA aptamer with the quantum dots</td><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Aptamer-based biosensors</td><td colspan="1" rowspan="1">0.1&#160;pg/mL</td><td colspan="1" rowspan="1">[<xref rid="bib81" ref-type="bibr">75</xref>]</td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Gold-immunochromatographic assay and enzyme-linked immunoassay</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">[<xref rid="bib96" ref-type="bibr">90</xref>]</td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Bio-barcode assay</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">[<xref rid="bib97" ref-type="bibr">[91]</xref>, <xref rid="bib98" ref-type="bibr">[92]</xref>, <xref rid="bib99" ref-type="bibr">[93]</xref>, <xref rid="bib100" ref-type="bibr">[94]</xref>]</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec3.2"><label>3.2</label><title>SARS-CoV-2 treatment strategies: a nanotechnology-based approach</title><p id="p0285">The main drawback of anti-viral drugs used for fighting against the virus causing COVID-19 is their non-specificity, which thus tends to be cytotoxic to the host cells. Remdesivir, chloroquine, favipiravir, atazanavir lopinavir/ritonavir, and daclatasvir have been tested in clinical trials as potential therapeutic drugs for SARS and other viral diseases. However, none of these antiviral drugs are definitive cures or suitable prophylaxis [<xref rid="bib103" ref-type="bibr">97</xref>]. The incorporation of these pharmaceuticals with the nano drug delivery systems can increase the solubility, biodistribution, and half-life of the drug in comparison to the pure drug used as such. Thus, novel therapies are required to combat COVID-19. Nanotechnology has opened up new avenues for developing antiviral therapies [<xref rid="bib104" ref-type="bibr">98</xref>,<xref rid="bib105" ref-type="bibr">99</xref>]. NPs are versatile in carrying the drug and targeting viruses, thus availing flexibility in therapeutic delivery. The inactivation of the virus at the host cell entry point may be one of the post-potent mechanisms aided through the usage of NPs to inhibit the SARS-CoV-2 spread. More additionally, its enhanced pharmacokinetics and biodistribution features improve the efficacy of currently available antiviral drugs [<xref rid="bib106" ref-type="bibr">100</xref>,<xref rid="bib107" ref-type="bibr">101</xref>]. Overall, progress in these approaches makes NPs appealing as a treatment for COVID-19. FDA-approved nanomaterials, including polymeric NPs [<xref rid="bib108" ref-type="bibr">102</xref>,<xref rid="bib109" ref-type="bibr">103</xref>], lipid-based NPs [<xref rid="bib110" ref-type="bibr">104</xref>,<xref rid="bib111" ref-type="bibr">105</xref>], metallic NPs [<xref rid="bib112" ref-type="bibr">106</xref>], dendrimers [<xref rid="bib113" ref-type="bibr">107</xref>], etc. are anticipated to be used to encapsulate antiviral drugs to accomplish long-term circulation, prolong release, and co-delivery of multiple drugs for improved clinical efficiency [<xref rid="bib114" ref-type="bibr">108</xref>,<xref rid="bib115" ref-type="bibr">109</xref>].</p><sec id="sec3.2.1"><label>3.2.1</label><title>Polymeric nanoparticles</title><p id="p0290">In recent years, polymeric NPs have gained a lot of attention due to their unique properties resulting from their nanoscale size [<xref rid="bib116" ref-type="bibr">110</xref>,<xref rid="bib117" ref-type="bibr">111</xref>]. The NP nano size offers several benefits to it such as its utilization as a promising drug carrier, it avails controlled delivery, aids protection to the bioactive molecules and drugs, and enhances the bioavailability and therapeutic efficacy [<xref rid="bib118" ref-type="bibr">[112]</xref>, <xref rid="bib119" ref-type="bibr">[113]</xref>, <xref rid="bib120" ref-type="bibr">[114]</xref>]. These properties of polymeric NPs can be taken advantage of to minimize the effects of viral infections [<xref rid="bib121" ref-type="bibr">115</xref>,<xref rid="bib122" ref-type="bibr">116</xref>]. For many years, researchers have efficiently utilized polymeric materials as antiviral agents, resulting in new classes of materials that hold promise for overcoming these obstacles [<xref rid="bib123" ref-type="bibr">117</xref>]. It can prevent viral infection and replication by adhering to the penetrating virus and inhibiting its entry into the host cell. Many polymers, synthetic and natural, have been reported as effective antiviral agents [<xref rid="bib124" ref-type="bibr">118</xref>,<xref rid="bib125" ref-type="bibr">119</xref>]. Chitosan, dextran, alginates, hyaluronic acid albumin, gelatin, and collagen are some of the natural polymers reported for their antiviral property [<xref rid="bib126" ref-type="bibr">120</xref>,<xref rid="bib127" ref-type="bibr">121</xref>]. Synthetic materials such as polyethylene glycol , N-(2-hydroxypropyl)-methacrylamide copolymer, Poly (lactic-co-glycolic acid) (PLGA), poly-1-glutamic acid, polystyrene maleic anhydride copolymer are some of the frequently used polymers for nano-drug delivery. Self-assembled copolymers, virus-like polymers, and cell membrane-coated NPs are the different types of polymeric-based nano-drug delivery systems [<xref rid="bib128" ref-type="bibr">122</xref>,<xref rid="bib129" ref-type="bibr">123</xref>].</p><p id="p0295">Seo-Yeon Jung et&#160;al. developed two forms of MERS-CoV vaccines: (i) spike protein NPs [where S trimers formed high ordered protein&#8211;protein micellular NPs] with alum adjuvant and (ii) a MERS-CoV spike gene encoded by a recombinant adenovirus serotype 5 (Ad5/MERS) [<xref rid="bib130" ref-type="bibr">124</xref>]. The group tested homologous and heterologous prime-boost vaccination strategies using the aforementioned two forms of vaccines. Furthermore, the body weight percent measured with the passing days post-infection stated that there was significantly less weight loss in the Ad5/MERS&#8211;spike protein and significantly least weight loss in the spike protein NPs vaccinated group in comparison to the non-vaccinated group post 3 days of infection (<xref rid="fig7" ref-type="fig">Fig.&#160;7</xref>
A). The lung histopathology results derived from the vaccinated mice (homologously vaccinated spike protein NPs or a heterologously vaccinated Ad5/MERS spike protein) in comparison to the non-vaccinated controls (PBS and Ad5/GFP) illustrated that the control groups, mice administered with Ad5/GFP and PBS, had the most serious lesions, indicating more a severe MERS-CoV infection, as also derived from the lesion scoring (<xref rid="fig7" ref-type="fig">Fig.&#160;7</xref>B and C).<fig id="fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>To guard against MERS-CoV infection, mice received either heterologous or homologous immunizations with spike protein nanoparticles and Ad5/MERS. (A) To ascertain if the viral infection led to a percentage gain or loss in weight, mice were weighed every day for five days following the vaccination. (B) Non-vaccinated controls (Ad5/green fluorescent protein and PBS) homologously or heterologously vaccinated with Ad5/MERS spike protein test mice groups or spike protein nanoparticles were histopathologically analyzed lesions were scored using their lung sections (C) Hematoxylin-eosin&#160;stained&#160;sections&#160;from&#160;lung&#160;tissues (Figures&#160;adopted from Vaccine, Elsevier [<xref rid="bib130" ref-type="bibr">124</xref>]).</p></caption><alt-text id="alttext0040">Fig.&#160;7</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7_lrg.jpg"/></fig></p><p id="p0300">Henceforth, the heterogeneous vaccination approach using viral vector-based vaccine priming and a protein NP-based vaccine as a booster dose will be most prophylactic to induce efficient immunity towards MERS-CoV infection through the induction of TH1 and TH2, both kinds of immune responses. This study suggests the use of a protein NP-based vaccine as a promising antiviral clinical strategy.</p><p id="p0305">The broad-spectrum antiviral drug, remdesivir, is currently being tested for its potential in combating SARS-CoV-2 infection <italic toggle="yes">in&#160;vitro</italic> as well as <italic toggle="yes">in&#160;vivo</italic>. But the clinical results were not so positive [<xref rid="bib131" ref-type="bibr">125</xref>]. Juanping Wu et&#160;al. theoretically designed an angiotensin-converting enzyme inhibitor&#8212;Lisinopril consisting of Poly (lactic-<italic toggle="yes">co-glycolic acid)</italic>NPs&#8212;loaded with remdesivir through coupling dissipative particle dynamics simulations and molecular docking (<xref rid="fig8" ref-type="fig">Fig.&#160;8</xref>
A). There was a potent interaction observed between remdesivir and RNA-dependent RNA polymerase (gthe intracellular target of remdesivir). The results inferred the importance of hydrogen bonding for remdesivir encapsulation. Later on, experimentally, with increasing remdesivir concentration, spherical NPs formation was availed but with higher concentrations precipitation was observed. Thus, the study highlighted the importance and emphasis of a logical framework and prior optimization for designing promising nano-formulations to combat SARS-CoV-2 infection [<xref rid="bib132" ref-type="bibr">126</xref>].<fig id="fig8" position="float" orientation="portrait"><label>Fig.&#160;8</label><caption><p>3D (A) and 2D (B) conformations of the Poly (lactic-<italic toggle="yes">co</italic>-glycolic acid) polymer and remdesivir binding. The final structures and the cross-sectional view of remdesivir-loaded L&#8211;Poly (lactic-<italic toggle="yes">co</italic>-glycolic acid) NPs (C) (Figures&#160;adopted from RSC published Phys. Chem. Chem. Phys. [<xref rid="bib132" ref-type="bibr">126</xref>]).</p></caption><alt-text id="alttext0045">Fig.&#160;8</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr8_lrg.jpg"/></fig></p><p id="p0310">Furthermore, the drugs, hydroxychloroquine (HCQ) and azithromycin (AZT), have already been clinically tested and have emerged as promising candidates in combating SARS-CoV-2 infection <italic toggle="yes">in&#160;vitro</italic> [<xref rid="bib133" ref-type="bibr">127</xref>,<xref rid="bib134" ref-type="bibr">128</xref>]. Synergistically, HCQ and AZT have shown more efficiency in reducing viral loads and thus fighting against the SARS-CoV-2 infection results in mortality reduction in comparison to the individual drugs [<xref rid="bib133" ref-type="bibr">127</xref>,<xref rid="bib135" ref-type="bibr">129</xref>]. de Barros AO et&#160;al. constructed two nanosystems (nanomicelles and polymeric NPs) for the delivery of HCQ and AZT, enhancing their efficacy with reduced side effects [<xref rid="bib134" ref-type="bibr">128</xref>].</p><p id="p0315">The results revealed a more efficient synergistic impact, indicative even at incredibly low concentrations (0.781&#160;g/mL). The viral multiplication can be significantly reduced, especially in the case of nanomicelles. Both NPs were capable of penetrating the lungs&#8217; interior part and also showed a long retention period (&gt;4&#160;h). AZT and HCQ-loaded polymeric nanosystems have shown to have antiviral effects and were non-cytotoxic in the <italic toggle="yes">in-vitro</italic> experiments. Therefore, when administered to the lungs, these NPs may provide a safer alternative to combat SARS-CoV-2 infection (<xref rid="fig9" ref-type="fig">Fig.&#160;9</xref>
).<fig id="fig9" position="float" orientation="portrait"><label>Fig.&#160;9</label><caption><p>The schematic diagram illustrates the two nanosystems (polymeric nanoparticles and nano micelles) for the delivery of hydroxychloroquineand azithromycin (Figure&#160;adopted from J. Nanostructure Chem. [<xref rid="bib134" ref-type="bibr">128</xref>]).</p></caption><alt-text id="alttext0050">Fig.&#160;9</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr9_lrg.jpg"/></fig></p><p id="p0320">Furthermore, IVM, an FDA-approved drug, can potentially inhibit SARS-CoV-2 replication as its potential in the NPencapsulated form has been proven against the ZIKA virus [<xref rid="bib136" ref-type="bibr">130</xref>,<xref rid="bib137" ref-type="bibr">131</xref>]. The study shows that IVM can accumulate in the blood at a higher concentration when it is introduced with a synthetic NP. Additionally, early research demonstrated that IVM delivered with NP can target the ZIKA's non-structural 1 protein. The IVM-loaded NPs increased the antiviral potency by keeping the IVM levels close to the lowest effective therapeutic dose but below the maximum permissible dose.</p><p id="p0325">Recently, Vanna Sanna et&#160;al. developed and prepared polymeric NPs for the targeted delivery of antiviral agents such as Remdesivir (RDV) [<xref rid="bib138" ref-type="bibr">132</xref>]. The RDV-loaded targeted NPs exhibited significantly enhanced antiviral efficacy compared to the free RDV at the same concentration. These findings indicated that by using such a NP-based targeted delivery system, pharmacologically efficient therapy against SARS-CoV-2 infection may be improved, paving the way for a cutting-edge and promising treatment for COVID-19 patients.</p><p id="p0330">Hu Tony Y and his research team discussed the impacts of nanomedicine on the efficiency of chloroquine against COVID-19 [<xref rid="bib139" ref-type="bibr">133</xref>]. They claimed that because of its small size (2&#8211;600&#160;nm) and spherical shape, the SARS-CoV-2 protein would behave like a NPand could be taken up by the host cell through a similar endocytosis mechanism. Another drug, Dexamethasone, which is an anti-inflammatory steroid, has been reported in aiding reduction in the number of patient deaths associated with COVID-19 by 35% [<xref rid="bib140" ref-type="bibr">134</xref>]. It has been proposed that dexamethasone as nanomedicine could aid in the ongoing management of COVID-19 disease. Dexamethasone nano-formulation could have an enhancing effect by boosting its bioavailability and its anti-inflammatory activity over time at the regions of the lungs highly inflamed due to hyper-activated immune cell populations in severely infected areas [<xref rid="bib141" ref-type="bibr">135</xref>]. Recently, the Swiss company, Bioavanta-Bosti, developed Novochizol&#8482;, an aerosol formulation of chitosan NPs that can be used alone or used as a nanocarrier to treat SARS-CoV-2 [<xref rid="bib142" ref-type="bibr">136</xref>]. Thus, the targeted drug delivery can be efficiently achieved by utilizing polymeric NPs for establishing promising vaccination and treatments to combat SARSCoV-2. The ability to modify several factors is inclusive of the loading capacity, tuning desired viscosity, and achieving shape and size confers polymeric NPs an additional benefit when applied as carriers in the design and the generation of potent SARS-CoV-2 infection treatments.</p></sec><sec id="sec3.2.2"><label>3.2.2</label><title>Metallic nanoparticles</title><p id="p0335">Metallic NPs are nanosized metals such as gold, silver, iron, etc. with at least one of the dimensions within 1&#8211;100&#160;nm. They exhibit unique properties that differ from their bulk counterparts, such as enhanced chemical reactivity, high surface area to volume ratio, and unique optical and electronic properties. These unique properties make metallic NPs useful in a wide range of applications, such as in medicine, catalysis, energy storage, and electronics. The use of metallic NPs as a treatment for SARS-CoV-2, the virus that causes COVID-19, is a research area of interest. Some studies have shown that certain metallic NPs , such as silver and AuNPs , have antiviral properties against the virus. For example, silver NPs have been shown to inactivate the virus by binding to its genetic material and disrupting its replication. However, it is important to note that the use of metallic NPs as a treatment for SARS-CoV-2 is still in the experimental stage, and more research is needed to determine their effectiveness and safety. Inorganic polyphosphate was encapsulated in silica/polyphosphate NPs [<xref rid="bib143" ref-type="bibr">137</xref>].</p></sec><sec id="sec3.2.3"><label>3.2.3</label><title>Lipid nanoparticles</title><p id="p0340">LNPs are being injected into the arms of billions of people as COVID-19 mRNA immunizations, fulfilling the promise of nanotechnology to revolutionize drug delivery [<xref rid="bib144" ref-type="bibr">138</xref>]. In clinical trials, the majority of pharmaceutical companies commonly use liposomes or LNPs as the carrier of the vaccine components to ensure stability and effective cargo delivery. BioNTech and Pfizer have developed the nucleoside-modified mRNA vaccine, BNT162b2 (Comirnaty&#174;), to combat COVID-19 [<xref rid="bib145" ref-type="bibr">139</xref>]. BNT162b2 is an mRNA vaccine formulated using LNPs , which showed 95% efficacy in the 3rd phase of the clinical trial. Another company, Moderna, also used the LNPs platform to deliver the vaccine mRNA-1893 [<xref rid="bib146" ref-type="bibr">140</xref>]. Additionally, LNPs enhance cellular and mucosal absorption while reducing the capacity of mucosal cilia to remove the vaccine system. mRNA molecules can be electrostatically attached to the interior core of a stable nanostructure formed by rapidly mixing lipid NPs and mRNA [<xref rid="bib147" ref-type="bibr">141</xref>]. This structural characteristic enhances the NPs&#8217; stability in physiological fluids and shields mRNA molecules from nuclease destruction. Modification with polyethylene glycol-lipids prolongs the blood circulation time of NPs and reduces renal filtration clearance and further diminishes the mononuclear phagocyte system recognition [<xref rid="bib146" ref-type="bibr">140</xref>,<xref rid="bib148" ref-type="bibr">142</xref>]. Additionally, by further tuning and strengthening the NPs , the targeted bio-distribution of the LNP -mRNA formulations can be enhanced [<xref rid="bib149" ref-type="bibr">143</xref>].</p></sec><sec id="sec3.2.4"><label>3.2.4</label><title>Antiviral-siRNA delivery</title><p id="p0345">An antiviral-siRNA treatment has been used to treat several serious human respiratory viruses, including MERS-CoV, SARS-CoV, RSV, and influenza virus, utilizing mice and non-human primates as model organisms [<xref rid="bib151" ref-type="bibr">144</xref>,<xref rid="bib152" ref-type="bibr">145</xref>]. Anti-SARS-CoV2 siRNA therapeutic application is already well-known [<xref rid="bib153" ref-type="bibr">146</xref>]. The employment of nanocarriers has the potential to significantly improve existing siRNA stability and fragile challenges. Ultimately, these nanocarriers may assist smart delivery systems, which can very efficiently deliver the entire siRNA payload into a desired tissue or organ in the body (<xref rid="fig10" ref-type="fig">Fig.&#160;10</xref>
) [<xref rid="bib150" ref-type="bibr">147</xref>]. Additionally, Poly(ethylene glycol), which has been well studied to stabilize NPs and enhance the <italic toggle="yes">in&#160;vivo</italic> circulation time, could also be used to tune the surface of nanocarriers [<xref rid="bib154" ref-type="bibr">148</xref>].<fig id="fig10" position="float" orientation="portrait"><label>Fig.&#160;10</label><caption><p>A schematic representation of the recommended method for treating SARS-CoV-2 infection using nano-carriers having multifunctionality; thus, could fulfill the antiviral siRNA delivery to the respiratory system (Figure&#160;adopted from Ref.&#160;[<xref rid="bib150" ref-type="bibr">147</xref>]).</p></caption><alt-text id="alttext0055">Fig.&#160;10</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr10_lrg.jpg"/></fig></p></sec><sec id="sec3.2.5"><label>3.2.5</label><title>Nanomaterials toxicity towards human health</title><p id="p0350">Overall, despite the effective success of nanotechnology-based approaches in SARS-CoV-2 treatment and antiviral therapeutics, there are some concerns about their toxicity and side effects in human body. The nanomaterial has its own pros and cons. In one hand, it acts as a very promising nanocarrier and improves the drug efficacy to prevent virus attachment, fusion, replication, and infection, or even prevent the inflammatory and harmful cascades that occur after a virus infection in patients but on the other hand, there are concerns with respect to its toxicity [<xref rid="bib155" ref-type="bibr">149</xref>,<xref rid="bib156" ref-type="bibr">150</xref>]. There are several findings of NPs, particularly the metallic NPs, which show detrimental effects such as mutagenicity, tumorigenicity, production of free radicals, etc. Precautions should be taken into consideration in relation to NP's toxicity, size and dose dependence, delivery method, biodistribution, and biodegradability [<xref rid="bib157" ref-type="bibr">151</xref>,<xref rid="bib158" ref-type="bibr">152</xref>] to avoid hazardous effects of nanomaterials on human health. Careful investigations are required to translate the applications of nanomaterials from <italic toggle="yes">in-vitro</italic> to clinical studies.</p></sec></sec><sec id="sec3.3"><label>3.3</label><title>SARS-CoV-2 prevention strategies: a nanotechnology based approach</title><p id="p0355">The WHO issued several suggestions for COVID-19 prevention and control as the SARS- CoV spreads more swiftly over the world [<xref rid="bib159" ref-type="bibr">[153]</xref>, <xref rid="bib160" ref-type="bibr">[154]</xref>, <xref rid="bib161" ref-type="bibr">[155]</xref>, <xref rid="bib162" ref-type="bibr">[156]</xref>, <xref rid="bib163" ref-type="bibr">[157]</xref>, <xref rid="bib164" ref-type="bibr">[158]</xref>, <xref rid="bib165" ref-type="bibr">[159]</xref>]. We can prevent viral infections by taking a few steps and implementing them into our daily lives. Potential exposures are managed by a variety of preventive measures in the areas where the COVID-19 virus is being transmitted widely. To control the COVID-19 community spread, temporary lockdown implementation and curfews execution were the first and foremost attempt. Moreover, the areas where a higher number of COVID-19 positive patients have been found were restricted by designating them as containment zones or hot spot locations. Public travel was completely prohibited to stop the further transmission of the virus. The major objective of the preventive measures is to isolate patients who are COVID-19 positive. Maintaining social distancing, frequent hand washing with soap, and carrying along hand sanitizers with 70&#8211;95% alcohol could avoid direct contact of the potent virus-infected hands to one&#8217;s face and lips.</p><p id="p0360">Two main transmissions are contributing to the widespread COVID-19: (i) human to human physical contact and (ii) through respiratory droplets emitted by the infected person [<xref rid="bib166" ref-type="bibr">160</xref>,<xref rid="bib167" ref-type="bibr">161</xref>]. Additionally, hospital environments are one of the serious concerns for potent SARS-CoV-2 spread because of the close contact between medical staff and COVID-19 patients [<xref rid="bib168" ref-type="bibr">162</xref>,<xref rid="bib169" ref-type="bibr">163</xref>]. The virus can swiftly be transmitted from the hospital staff members to their families and in the communities. Due to their frequent exposure to the infectious environment, healthcare workers must be protected from SARS-CoV-2 infection risk to reduce the frequency of illnesses and breakouts during the pandemic. Facemasks and gloves have gained widespread acceptance as efficient methods for the spread of SARS-CoV-2 since the COVID-19 pandemic. Moreover, personal protective equipment (PPE) kits are also being widely used as a likely promising preventive measure in hospitals. One of the many problems that COVID warriors must handle is the severe skin rashes that can result from the prolonged usage of gloves, PPE, and facemasks, which play the role of COVID-19 preventive wearables [<xref rid="bib170" ref-type="bibr">164</xref>]. More desirable properties can be inferred from these COVID-19 preventive wearables by implementing nanotechnology in their design and manufacturing. As a result, more cost-effective, smart, hydrophobic, breathable, one with enhanced antimicrobial activity, and effective solutions can be derived as improvement in the existing COVID-19 preventive wearables [<xref rid="bib170" ref-type="bibr">[164]</xref>, <xref rid="bib171" ref-type="bibr">[165]</xref>, <xref rid="bib172" ref-type="bibr">[166]</xref>, <xref rid="bib173" ref-type="bibr">[167]</xref>].</p><sec id="sec3.3.1"><label>3.3.1</label><title>PPE kits</title><p id="p0365">Applications of nanotechnology in the textile industry for fabrication can confer antimicrobial properties to PPE kits [<xref rid="bib172" ref-type="bibr">166</xref>]. Metallic nanomaterials such as AgNPs embedded in fabrics have already been proven for their antimicrobial properties [<xref rid="bib174" ref-type="bibr">[168]</xref>, <xref rid="bib175" ref-type="bibr">[169]</xref>, <xref rid="bib176" ref-type="bibr">[170]</xref>]. AgNPs have also been demonstrated to be used in face masks, lab coats, etc. and have potent antimicrobial functionality [<xref rid="bib177" ref-type="bibr">171</xref>]. Bhattacharjee Shovon et&#160;al. reported that graphene or graphene-based materials can be incorporated into the fabrics, which can further avail special properties like antibacterial, mechanical strength, fire resistance, abrasion resistance capacity, and ultraviolet-protection and can also make it lighter in weight [<xref rid="bib178" ref-type="bibr">172</xref>] (<xref rid="fig11" ref-type="fig">Fig.&#160;11</xref>
).<fig id="fig11" position="float" orientation="portrait"><label>Fig.&#160;11</label><caption><p>A schematic illustration describing the multiple benefits of graphene-modified protective clothing [<xref rid="bib178" ref-type="bibr">172</xref>].</p></caption><alt-text id="alttext0060">Fig.&#160;11</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr11_lrg.jpg"/></fig></p><p id="p0370">The hydrophobicity and breathability of the cloth are unaffected by NPs. To strengthen their usage as filters and possible antimicrobial agents, metal NPs like copper and silver can be considered potent options. The silver or copper NPs can be incorporated with the materials like polyester, cotton, cellulose-based fabric, and polyamide [<xref rid="bib179" ref-type="bibr">173</xref>,<xref rid="bib180" ref-type="bibr">174</xref>].</p></sec><sec id="sec3.3.2"><label>3.3.2</label><title>Facemasks</title><p id="p0375">Face masks made up of silver and copper NPs -coated dual layer have been developed. Incorporating NPs proves more effective due to virucidal properties of the respiratory face masks [<xref rid="bib181" ref-type="bibr">175</xref>]. A disposable facemask constructed of cellulose nanofibers and equipped with a filter cartridge developed by Queensland University of Technology, Australia, is capable of filtering particles &lt;100&#160;nm [<xref rid="bib173" ref-type="bibr">167</xref>]. Furthermore, a reusable mask produced by LIGC Applications Ltd., USA, using a graphene foam with microporosity can capture and thus eliminate pathogenic microorganisms/SARS-CoV-2 due to its conductive electrical charge [<xref rid="bib182" ref-type="bibr">176</xref>]. Nanofibers were manufactured employing insulation and a block electrospinning procedure [<xref rid="bib183" ref-type="bibr">177</xref>]. The air filter's pressure was reduced by the orthogonal structure of the nanofibers, which enhanced filtration. The nanofiber-based facemasks have a high filtration capacity, are water-resistant, and remain functional even after multiple washing [<xref rid="bib184" ref-type="bibr">178</xref>].</p></sec><sec id="sec3.3.3"><label>3.3.3</label><title>Ocular protection</title><p id="p0380">Ocular protection is highly important to eliminate the threat of SARS-CoV-2 transmission through the eyes of medical professionals and other healthcare workers [<xref rid="bib185" ref-type="bibr">[179]</xref>, <xref rid="bib186" ref-type="bibr">[180]</xref>, <xref rid="bib187" ref-type="bibr">[181]</xref>]. Natural materials are proven to offer a variety of bioactive qualities, including anticancer, antiviral, and antidiabetic [<xref rid="bib118" ref-type="bibr">[112]</xref>, <xref rid="bib119" ref-type="bibr">[113]</xref>, <xref rid="bib120" ref-type="bibr">[114]</xref>,<xref rid="bib123" ref-type="bibr">117</xref>]. The 121 amino acid lectin &#8216;Griffithsin&#8217;, which is produced from the red alga Griffithsia spp., has demonstrated antiviral effectiveness against HIV, MERS-CoV, SARS-CoV, etc. It prevents the entry of the aforementioned viruses by interacting with the various glycoproteins on the viral envelope [<xref rid="bib188" ref-type="bibr">182</xref>]. Despite having great potential, it has some limitations like low bioavailability. Lixiang Wang and Yingping Deng reported that during the SARS-CoV outbreak, medical professionals may benefit from promising ocular protection provided by contact lenses containing Griffithsin NPs by likely preventing the high risk of SARS-CoV-2 exposure [<xref rid="bib187" ref-type="bibr">181</xref>]. In the present pandemic, the usage of Griffithsin with sustained release in the form of NPs as therapeutic contact lenses can provide promising eye protection from further SARS-CoV-2 infection.</p></sec><sec id="sec3.3.4"><label>3.3.4</label><title>Sanitizers and disinfectants</title><p id="p0385">Maintaining good hand hygiene has become a crucial component in the war against coronavirus. A well-accepted principle in the prevention of disease transmission, proper hand hygiene offers a 24&#8211;31% possibility of limiting the spread of transmissible disease [<xref rid="bib189" ref-type="bibr">183</xref>]. The Centers for Disease Control and Prevention advises routine hand washing with soap and water for 20&#160;s to stop the spread of viruses; if soap and water are not available, hand sanitizer with at least 60% alcohol can be used. Instead of chemical disinfectants, the NPs of metals like silver, titanium, and copper with antiviral properties can be utilized to prevent SARS-CoV2. A multipurpose sanitizer with a nanosilver base that is non-irritating and environmentally friendly has been introduced [<xref rid="bib183" ref-type="bibr">177</xref>,<xref rid="bib190" ref-type="bibr">184</xref>]. Additionally, the Italian company Nano, TechSurface, has invented a disinfecting solution consisting of titanium dioxide and silver ions [<xref rid="bib184" ref-type="bibr">178</xref>]. The nanopolymer-based disinfectants exhibit a potent antibacterial and antiviral action and are simple to manufacture [<xref rid="bib191" ref-type="bibr">185</xref>]. It has advantages over those based on chemicals as it is economical, non-flammable, and biodegradable.</p><p id="p0390">In light of the COVID-19 pandemic, biocontamination in various medical equipment and other surfaces are a critical point to be considered and taken care of. Superhydrophobic nanocoatings might be utilized to prevent the transmission of viruses. By dispersing copper NPs in a flexible polymer matrix with the use of a solvent like acetone, super-hydrophobic nanocoatings are generated [<xref rid="bib192" ref-type="bibr">186</xref>]. Copper NPs also have antibacterial and antiviral properties. Glass surfaces can be nanocoated by using copper and bilayer titanium [<xref rid="bib193" ref-type="bibr">187</xref>,<xref rid="bib194" ref-type="bibr">188</xref>]. Since the majority of medical devices are composed of stainless steel, silver NPs have also been used to coat stainless steel surfaces [<xref rid="bib195" ref-type="bibr">189</xref>].</p><p id="p0395">Almanza-Reyes Horacio et&#160;al. synthesized AgNPs and claimed the first-ever study where NPs were utilized as a constituent of the solution used for rinsing the nose and the mouthwash. This aid benefits the healthcare staff directly working in close contact with the person suffering from COVID-19 [<xref rid="bib196" ref-type="bibr">190</xref>]. According to the study, the use of AgNPs in the mouthwash and nasal rinses can lower the incidence of SARS-CoV-2 infection. The results derived from this experiment are interesting and promising. The number of COVID-19 patients that the medical staff visited caused them to be exposed to an elevated viral load (each staff member attending an average of 169 patients per week), but in turn did not suffer through SARS-CoV-2 infection. This resistance was a beneficiary result of using AgNPs in the nasal rinse solution and mouthwash [<xref rid="bib197" ref-type="bibr">191</xref>]. Thus, the utilization of AgNPs in nasal rinsing solutions and the mouthwash would be particularly advantageous as a promising preventive measure for inhibiting SARS-CoV-2 infection and its further transmission, not for only healthcare professionals but also the general public. Various nanomaterials used for the prevention of SARS-CoV-2 infection are listed in <xref rid="tbl2" ref-type="table">Table&#160;2</xref>
.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table&#160;2</label><caption><p>Nanomaterials used for the prevention of SARS-CoV-2 infection.</p></caption><alt-text id="alttext0070">Table&#160;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sr. No.</th><th colspan="1" rowspan="1">Nanomaterial</th><th colspan="1" rowspan="1">Uses for</th><th colspan="1" rowspan="1">Function/properties</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Graphene-based materials</td><td colspan="1" rowspan="1">Personal protective equipment kit</td><td colspan="1" rowspan="1">Antibacterial, mechanical strength, fire resistance, abrasion resistance capacity, and ultraviolet-protection</td><td colspan="1" rowspan="1">[<xref rid="bib178" ref-type="bibr">172</xref>]</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Cellulose nanofibers</td><td colspan="1" rowspan="1">Face mask</td><td colspan="1" rowspan="1">Capable of filtering particles &lt;100&#160;nm</td><td colspan="1" rowspan="1">[<xref rid="bib173" ref-type="bibr">167</xref>]</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Graphene foam</td><td colspan="1" rowspan="1">Reusable mask</td><td colspan="1" rowspan="1">Eliminate pathogenic microorganisms/SARS-CoV-2 due to its conductive electrical charge</td><td colspan="1" rowspan="1">[<xref rid="bib182" ref-type="bibr">176</xref>]</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Nanofibers</td><td colspan="1" rowspan="1">Face mask</td><td colspan="1" rowspan="1">High filtration capacity, are water-resistant, and remain functional even after multiple washing</td><td colspan="1" rowspan="1">[<xref rid="bib184" ref-type="bibr">178</xref>]</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">Griffithsin nanoparticles</td><td colspan="1" rowspan="1">Contact lenses</td><td colspan="1" rowspan="1">Provide promising eye protection from further SARS-CoV-2 infection</td><td colspan="1" rowspan="1">[<xref rid="bib187" ref-type="bibr">181</xref>]</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">Silver nanoparticles</td><td colspan="1" rowspan="1">Sanitizer</td><td colspan="1" rowspan="1">Non-irritating and environmentally friendly</td><td colspan="1" rowspan="1">[<xref rid="bib155" ref-type="bibr">149</xref>,<xref rid="bib162" ref-type="bibr">156</xref>]</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">Titanium dioxide and silver ions-based nano polymers</td><td colspan="1" rowspan="1">Disinfectants</td><td colspan="1" rowspan="1">Potent antibacterial and antiviral action, economical, non-flammable, and biodegradable</td><td colspan="1" rowspan="1">[<xref rid="bib184" ref-type="bibr">178</xref>,<xref rid="bib191" ref-type="bibr">185</xref>]</td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">Copper nanoparticles and bilayer titanium</td><td colspan="1" rowspan="1">Nanocoatings to medical equipments and other surfaces</td><td colspan="1" rowspan="1">Antibacterial and antiviral properties</td><td colspan="1" rowspan="1">[<xref rid="bib192" ref-type="bibr">[186]</xref>, <xref rid="bib193" ref-type="bibr">[187]</xref>, <xref rid="bib194" ref-type="bibr">[188]</xref>]</td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">Silver nanoparticles</td><td colspan="1" rowspan="1">Nose and the mouthwash</td><td colspan="1" rowspan="1">Lower the incidence of SARS-CoV-2 infection from patients to the medical staff as well as the general public</td><td colspan="1" rowspan="1">[<xref rid="bib196" ref-type="bibr">190</xref>]</td></tr></tbody></table></table-wrap></p></sec></sec></sec><sec id="sec4"><label>4</label><title>Conclusion and future perspectives</title><p id="p0400">In this article, we have summarized the most recent information available on SARS-CoV-2's origin, morphology, structure, genomic organization, pathophysiology, mode of spread, and symptoms. The current diagnosis and available treatment options along with their limitations were also explored. Here, we have discussed several nanomaterials used for the diagnosis of SARS-CoV-2. A nanomaterial offers a myriad of benefits including excellent reproducibility, sensitivity, quick detection time, uncomplicated operation, and minimal cost. Colorimetric assays and nano-immunosensors provide extreme sensitivity and are cost-effective as well. The discipline of nanotechnology has immense potential to provide definitive cure and prevention measures as compared to the limitations faced by the healthcare system. It has paved the way for novel approaches for the sensitive and specific detection system, which has proven to be more precise for identification and diagnosis.</p><p id="p0405">Further, we have discussed several NPs used to enhance the antiviral activity of the already-existing antiviral agents or developing a wholly new antiviral mechanism. Nano-architectured vaccines are considered to be risk-free and 95% effective. For the preventive measurements, we have gone through the SARS-CoV-2 prevention strategies using nanomaterials. The applications of nanotechnology have been explored for bringing out preventive measures. Nanomaterial-modified PPE kits, face masks, gloves, lab coats, etc. can be effectively used for their enhanced antimicrobial properties, cost-effectiveness, better mechanical strength, high conductivity, non-irritating quality, environment-friendly, etc. Synthesized AgNPs are inspected to be highly advantageous as they are considered to be the first NPs that can be used for the mouthwash and nasal rinsing, which subsequently lowers the threat of SARS-CoV-2 infection spread.</p><p id="p0410">Henceforth, the swift advancement in the field of nanotechnology seems to be promising; however, to retrieve the fundamental information and improve the present knowledge on nano-medicine and its potential benefits, it should be critically studied and scrutinized. Currently, there are several ongoing clinical trials on their usage that can be tremendously helpful in offering better strategies, in-depth understanding, finer treatment, and preventive measures in an attempt to battle the infectious coronavirus more strongly, specifically, and potently. Researchers would be benefitted from the nanotechnology-based methodologies discussed in this study and aid in generating novel COVID-19 diagnostic and treatment modalities.</p></sec><sec id="sec5"><title>Credit author statement</title><p id="p0415"><bold>Raghu Solanki:</bold> conceptualization, writing-original draft preparation, and validation <bold>Ashvarya Shankar:</bold> writing-original draft preparation and visualization <bold>Unnati Modi:</bold> writing-reviewing and editing and validation <bold>Sunita Patel:</bold> supervision and writing- reviewing and editing.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0425">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>K.S.M.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>E.H.Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.Y.</given-names></name></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus&#8211;infected pneumonia</article-title><source>N.&#160;Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">31995857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001316</pub-id><pub-id pub-id-type="pmcid">PMC7121484</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Holshue</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>DeBolt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lindquist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lofy</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Wiesman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>H.</given-names></name><name name-style="western"><surname>Spitters</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ericson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wilkerson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tural</surname><given-names>A.</given-names></name></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N.&#160;Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>929</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">32004427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001191</pub-id><pub-id pub-id-type="pmcid">PMC7092802</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Mandourah</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Al-Hameed</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sindi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Almekhlafi</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jose</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Al-Omari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kharaba</surname><given-names>A.</given-names></name></person-group><article-title>Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome</article-title><source>Am. J. Respir. Crit. Care Med.</source><volume>197</volume><year>2018</year><fpage>757</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">29161116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201706-1172OC</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Talotta</surname><given-names>R.</given-names></name></person-group><article-title>Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to &#8220;potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases</article-title><source>Clin. Immunol.</source><volume>224</volume><year>2021</year><object-id pub-id-type="publisher-id">108665</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2021.108665</pub-id><pub-id pub-id-type="pmcid">PMC7833091</pub-id><pub-id pub-id-type="pmid">33429060</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Cardoso</surname><given-names>V.M. de O.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Comparetti</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Sampaio</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>L.M.B.</given-names></name><name name-style="western"><surname>Lins</surname><given-names>P.M.P.</given-names></name><name name-style="western"><surname>Zucolotto</surname><given-names>V.</given-names></name></person-group><article-title>Is nanotechnology helping in the fight against COVID-19?</article-title><source>Front. Nanotechnol.</source><year>2020</year><fpage>4</fpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Knezevic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Peden</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.-N.</given-names></name></person-group><article-title>Development of mRNA vaccines: scientific and regulatory issues</article-title><source>Vaccines (Basel).</source><volume>9</volume><year>2021</year><fpage>81</fpage><pub-id pub-id-type="pmid">33498787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9020081</pub-id><pub-id pub-id-type="pmcid">PMC7910833</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Reichmuth</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Oberli</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jaklenec</surname><given-names>A.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blankschtein</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccine delivery using lipid nanoparticles</article-title><source>Ther. Deliv.</source><volume>7</volume><year>2016</year><fpage>319</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">27075952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/tde-2016-0006</pub-id><pub-id pub-id-type="pmcid">PMC5439223</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Tyrrell</surname><given-names>D.A.J.</given-names></name><name name-style="western"><surname>Bynoe</surname><given-names>M.L.</given-names></name></person-group><article-title>Cultivation of viruses from a high proportion of patients with colds</article-title><source>Lancet</source><year>1966</year><fpage>76</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">4158999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(66)92364-6</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Tyrrell</surname><given-names>D.A.J.</given-names></name></person-group><article-title>The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture</article-title><source>J.&#160;Gen. Virol.</source><volume>1</volume><year>1967</year><fpage>175</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">4293939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/0022-1317-1-2-175</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Talbot</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Jacomy</surname><given-names>H.</given-names></name><name name-style="western"><surname>Desforges</surname><given-names>M.</given-names></name></person-group><article-title>Pathogenesis of human coronaviruses other than severe acute respiratory syndrome coronavirus</article-title><source>Nidoviruses</source><year>2007</year><fpage>313</fpage><lpage>324</lpage></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.-R.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q.-D.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Z.-S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.-D.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>K.-S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.-Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name></person-group><article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak&#8211;an update on the status</article-title><source>Mil. Med. Res.</source><volume>7</volume><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">32169119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40779-020-00240-0</pub-id><pub-id pub-id-type="pmcid">PMC7068984</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="book" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nyodu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maurya</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>S.K.</given-names></name></person-group><part-title>Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</part-title><source>Coronavirus Disease 2019 (COVID-19)</source><year>2020</year><publisher-name>Springer</publisher-name><fpage>23</fpage><lpage>31</lpage></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Potdar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cherian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Team</surname><given-names>I.C.</given-names></name></person-group><article-title>Transmission electron microscopy imaging of SARS-CoV-2</article-title><source>Indian J. Med. Res.</source><volume>151</volume><year>2020</year><fpage>241</fpage><pub-id pub-id-type="pmid">32362648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijmr.IJMR_577_20</pub-id><pub-id pub-id-type="pmcid">PMC7224615</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Pal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berhanu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Desalegn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kandi</surname><given-names>V.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update</article-title><source>Cureus</source><volume>12</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.7423</pub-id><pub-id pub-id-type="pmcid">PMC7182166</pub-id><pub-id pub-id-type="pmid">32337143</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>To</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>S.A.</given-names></name></person-group><article-title>SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway</article-title><source>iScience</source><volume>24</volume><year>2021</year><object-id pub-id-type="publisher-id">102295</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2021.102295</pub-id><pub-id pub-id-type="pmcid">PMC7939994</pub-id><pub-id pub-id-type="pmid">33718825</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Finlay</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>See</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Brunham</surname><given-names>R.C.</given-names></name></person-group><article-title>Rapid response research to emerging infectious diseases: lessons from SARS</article-title><source>Nat. Rev. Microbiol.</source><volume>2</volume><year>2004</year><fpage>602</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">15197395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro930</pub-id><pub-id pub-id-type="pmcid">PMC7097457</pub-id></element-citation></ref><ref id="bib19"><label>18</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Gamble</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Tamin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harcourt</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Thornburg</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>S.I.</given-names></name></person-group><article-title>Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1</article-title><source>N.&#160;Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1564</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">32182409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2004973</pub-id><pub-id pub-id-type="pmcid">PMC7121658</pub-id></element-citation></ref><ref id="bib20"><label>19</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>S.W.X.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>O.T.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M.S.Y.</given-names></name><name name-style="western"><surname>Marimuthu</surname><given-names>K.</given-names></name></person-group><article-title>Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1610</fpage><lpage>1612</lpage><pub-id pub-id-type="pmid">32129805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.3227</pub-id><pub-id pub-id-type="pmcid">PMC7057172</pub-id></element-citation></ref><ref id="bib21"><label>20</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Yeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>D.</given-names></name></person-group><article-title>Enteric involvement of coronaviruses: is faecal&#8211;oral transmission of SARS-CoV-2 possible?</article-title><source>Lancet Gastroenterol. Hepatol.</source><volume>5</volume><year>2020</year><fpage>335</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">32087098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(20)30048-0</pub-id><pub-id pub-id-type="pmcid">PMC7130008</pub-id></element-citation></ref><ref id="bib22"><label>21</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Kotlyar</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Grechukhina</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Popkhadze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grimshaw</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tal</surname><given-names>O.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Tal</surname><given-names>R.</given-names></name></person-group><article-title>Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis</article-title><source>Am. J. Obstet. Gynecol.</source><volume>224</volume><year>2021</year><fpage>35</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">32739398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2020.07.049</pub-id><pub-id pub-id-type="pmcid">PMC7392880</pub-id></element-citation></ref><ref id="bib25"><label>22</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Boopathi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poma</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Kolandaivel</surname><given-names>P.</given-names></name></person-group><article-title>Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment</article-title><source>J.&#160;Biomol. Struct. Dyn.</source><volume>39</volume><year>2021</year><fpage>3409</fpage><lpage>3418</lpage><pub-id pub-id-type="pmid">32306836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1758788</pub-id><pub-id pub-id-type="pmcid">PMC7196923</pub-id></element-citation></ref><ref id="bib28"><label>23</label><element-citation publication-type="book" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Council</surname><given-names>I.</given-names></name></person-group><part-title>Till Date , 162 Antigen Based Rapid Test Kits have been Validated (Including 33 Revalidations), and the Following are Found to be Satisfactory</part-title><year>2022</year></element-citation></ref><ref id="bib29"><label>24</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>H.Y.F.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>H.Y.S.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>A.H.-T.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>T.W.-Y.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>C.S.Y.</given-names></name><name name-style="western"><surname>Lui</surname><given-names>M.M.-S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.C.Y.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>K.W.-H.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>T.</given-names></name></person-group><article-title>Frequency and distribution of chest radiographic findings in COVID-19 positive patients</article-title><source>Radiology</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2020201160</pub-id><pub-id pub-id-type="pmcid">PMC7233401</pub-id><pub-id pub-id-type="pmid">32216717</pub-id></element-citation></ref><ref id="bib30"><label>25</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Jacobi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bernheim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eber</surname><given-names>C.</given-names></name></person-group><article-title>Portable chest X-ray in coronavirus disease-19 (COVID-19): a pictorial review</article-title><source>Clin. Imag.</source><volume>64</volume><year>2020</year><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinimag.2020.04.001</pub-id><pub-id pub-id-type="pmcid">PMC7141645</pub-id><pub-id pub-id-type="pmid">32302927</pub-id></element-citation></ref><ref id="bib31"><label>26</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Sreepadmanabh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Chande</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19: advances in diagnostic tools, treatment strategies, and vaccine development</article-title><source>J.&#160;Biosci.</source><volume>45</volume><year>2020</year><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">33410425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12038-020-00114-6</pub-id><pub-id pub-id-type="pmcid">PMC7683586</pub-id></element-citation></ref><ref id="bib32"><label>27</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Oladipo</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Ajayi</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Odeyemi</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Akindiya</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Adebayo</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Oguntomi</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Oyewole</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Jimah</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Oladipo</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ariyo</surname><given-names>O.E.</given-names></name></person-group><article-title>Laboratory diagnosis of COVID-19 in Africa: availability, challenges and implications</article-title><source>Drug Discov. Ther.</source><volume>14</volume><year>2020</year><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">32908070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5582/ddt.2020.03067</pub-id></element-citation></ref><ref id="bib33"><label>28</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Udugama</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kadhiresan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kozlowski</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Malekjahani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>V.Y.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mubareka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gubbay</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.C.W.</given-names></name></person-group><article-title>Diagnosing COVID-19: the disease and tools for detection</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>3822</fpage><lpage>3835</lpage><pub-id pub-id-type="pmid">32223179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c02624</pub-id></element-citation></ref><ref id="bib35"><label>29</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Bandaru</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rout</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kamble</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Samal</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Gorain</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Kesharwani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dandela</surname><given-names>R.</given-names></name></person-group><article-title>Clinical progress of therapeutics and vaccines: rising hope against COVID-19 treatment</article-title><source>Process Biochem.</source><volume>118</volume><year>2022</year><fpage>154</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">35437418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.procbio.2022.04.011</pub-id><pub-id pub-id-type="pmcid">PMC9008982</pub-id></element-citation></ref><ref id="bib36"><label>30</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><collab>Serum Institute of India Pvt. Ltd</collab></person-group><article-title>ChAdOx1 nCoV- 19 corona virus vaccine (recombinant) in prevention of (COVID-19)</article-title><source>Disease</source><year>2021</year><fpage>2</fpage></element-citation></ref><ref id="bib37"><label>31</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sajid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jahan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Adelusi</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Maitra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>A&#160;secondary approach with conventional medicines and supplements to recuperate current COVID-19 status</article-title><source>Biomed. Pharmacother.</source><volume>142</volume><year>2021</year><object-id pub-id-type="publisher-id">111956</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111956</pub-id><pub-id pub-id-type="pmcid">PMC8313489</pub-id><pub-id pub-id-type="pmid">34332377</pub-id></element-citation></ref><ref id="bib38"><label>32</label><element-citation publication-type="book" id="sref38"><person-group person-group-type="author"><collab>B. Biotech</collab></person-group><part-title>Restricted use in emergency situation of COVID-19 SARS-CoV-2 Vaccine</part-title><year>2019</year><object-id pub-id-type="publisher-id">500078</object-id></element-citation></ref><ref id="bib39"><label>33</label><mixed-citation publication-type="other" id="sref39">M.C.M. Lapitan, M.A. Castor, J.P. Gomez, Among Persons at Risk, What is the Clinical Efficacy, Effectiveness and Safety of BBIBP-CorV (Sinopharm) in the Prevention of SARS-CoV-2 Infection?, ((n.d.)).</mixed-citation></ref><ref id="bib40"><label>34</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name></person-group><article-title>Confronting the threat of SARS-CoV-2: realities, challenges and therapeutic strategies</article-title><source>Exp. Ther. Med.</source><volume>21</volume><year>2021</year><fpage>1</fpage><pub-id pub-id-type="pmid">33456522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2020.9587</pub-id><pub-id pub-id-type="pmcid">PMC7807638</pub-id></element-citation></ref><ref id="bib41"><label>35</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Halperin</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>MacKinnon-Cameron</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cahn</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Ruiz-Palacios</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lanas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guerrero</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>S.R.M.</given-names></name></person-group><article-title>Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial</article-title><source>Lancet</source><volume>399</volume><year>2022</year><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">34953526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02753-7</pub-id><pub-id pub-id-type="pmcid">PMC8700283</pub-id></element-citation></ref><ref id="bib42"><label>36</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.-J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>384</volume><year>2009</year><fpage>486</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">19422787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2009.05.003</pub-id><pub-id pub-id-type="pmcid">PMC2750803</pub-id></element-citation></ref><ref id="bib43"><label>37</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Parida</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Alekhya</surname><given-names>G.</given-names></name><name name-style="western"><surname>Subba</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Padhy</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Patro</surname><given-names>B.K.</given-names></name></person-group><article-title>Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India</article-title><source>J.&#160;Med. Virol.</source><volume>94</volume><year>2022</year><fpage>2453</fpage><lpage>2459</lpage><pub-id pub-id-type="pmid">35149993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.27655</pub-id><pub-id pub-id-type="pmcid">PMC9088522</pub-id></element-citation></ref><ref id="bib44"><label>38</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Ghasemiyeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mohammadi-Samani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Firouzabadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dehshahri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vazin</surname><given-names>A.</given-names></name></person-group><article-title>A&#160;focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines</article-title><source>Int. Immunopharm.</source><volume>100</volume><year>2021</year><object-id pub-id-type="publisher-id">108162</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2021.108162</pub-id><pub-id pub-id-type="pmcid">PMC8445802</pub-id><pub-id pub-id-type="pmid">34562844</pub-id></element-citation></ref><ref id="bib45"><label>39</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M.S.</given-names></name></person-group><article-title>Early approval of COVID-19 vaccines: pros and cons</article-title><source>Hum. Vaccines Immunother.</source><volume>17</volume><year>2021</year><fpage>3288</fpage><lpage>3296</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2021.1944742</pub-id><pub-id pub-id-type="pmcid">PMC8437465</pub-id><pub-id pub-id-type="pmid">34283001</pub-id></element-citation></ref><ref id="bib46"><label>40</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Jasny</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Horscroft</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schanen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Geter</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fotin-Mleczek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petsch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wittman</surname><given-names>V.</given-names></name></person-group><article-title>Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response</article-title><source>J.&#160;Transl. Med.</source><volume>15</volume><year>2017</year><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">28049494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-016-1111-6</pub-id><pub-id pub-id-type="pmcid">PMC5210268</pub-id></element-citation></ref><ref id="bib47"><label>41</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Lembo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Donalisio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Civra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Argenziano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>R.</given-names></name></person-group><article-title>Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections</article-title><source>Expet Opin. Drug Deliv.</source><volume>15</volume><year>2018</year><fpage>93</fpage><lpage>114</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425247.2017.1360863</pub-id><pub-id pub-id-type="pmid">28749739</pub-id></element-citation></ref><ref id="bib48"><label>42</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>G.E.M.</given-names></name><name name-style="western"><surname>Govender</surname><given-names>T.</given-names></name><name name-style="western"><surname>Parboosing</surname><given-names>R.</given-names></name></person-group><article-title>The role of nanotechnology in the treatment of viral infections</article-title><source>Ther. Adv. Infect Dis.</source><volume>4</volume><year>2017</year><fpage>105</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">28748089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2049936117713593</pub-id><pub-id pub-id-type="pmcid">PMC5507392</pub-id></element-citation></ref><ref id="bib49"><label>43</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz-Hitzky</surname><given-names>E.</given-names></name><name name-style="western"><surname>Darder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wicklein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ruiz-Garcia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mart&#237;n-Sampedro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Del Real</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aranda</surname><given-names>P.</given-names></name></person-group><article-title>Nanotechnology responses to COVID-19</article-title><source>Adv. Healthc. Mater.</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">2000979</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202000979</pub-id><pub-id pub-id-type="pmid">32885616</pub-id></element-citation></ref><ref id="bib50"><label>44</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Yorseng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Siengchin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ashok</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rajulu</surname><given-names>A.V.</given-names></name></person-group><article-title>Nanocomposite egg shell powder with in situ generated silver nanoparticles using inherent collagen as reducing agent</article-title><source>J.&#160;Bioresour. Bioprod.</source><volume>5</volume><year>2020</year><fpage>101</fpage><lpage>107</lpage></element-citation></ref><ref id="bib51"><label>45</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sagarika</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Sabu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kalarikkal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name></person-group><article-title>Cellulose nanocomposites: fabrication and biomedical applications</article-title><source>J.&#160;Bioresour. Bioprod.</source><volume>5</volume><year>2020</year><fpage>223</fpage><lpage>237</lpage></element-citation></ref><ref id="bib52"><label>46</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Braeckmans</surname><given-names>K.</given-names></name></person-group><article-title>Stimuli-responsive nanobubbles for biomedical applications</article-title><source>Chem. Soc. Rev.</source><volume>50</volume><year>2021</year><fpage>5746</fpage><lpage>5776</lpage><pub-id pub-id-type="pmid">33972972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9cs00839j</pub-id></element-citation></ref><ref id="bib53"><label>47</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Cavalcanti</surname><given-names>I.D.L.</given-names></name><name name-style="western"><surname>Cajuba de Britto Lira Nogueira</surname><given-names>M.</given-names></name></person-group><article-title>Pharmaceutical nanotechnology: which products are been designed against COVID-19?</article-title><source>J.&#160;Nanoparticle Res.</source><volume>22</volume><year>2020</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11051-020-05010-6</pub-id><pub-id pub-id-type="pmcid">PMC7480001</pub-id><pub-id pub-id-type="pmid">32922162</pub-id></element-citation></ref><ref id="bib54"><label>48</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Merisko-Liversidge</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Liversidge</surname><given-names>G.G.</given-names></name></person-group><article-title>Drug nanoparticles: formulating poorly water-soluble compounds</article-title><source>Toxicol. Pathol.</source><volume>36</volume><year>2008</year><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">18337220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0192623307310946</pub-id></element-citation></ref><ref id="bib55"><label>49</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H.</given-names></name></person-group><article-title>PEGylated nanographene oxide for delivery of water-insoluble cancer drugs</article-title><source>J.&#160;Am. Chem. Soc.</source><volume>130</volume><year>2008</year><fpage>10876</fpage><lpage>10877</lpage><pub-id pub-id-type="pmid">18661992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja803688x</pub-id><pub-id pub-id-type="pmcid">PMC2597374</pub-id></element-citation></ref><ref id="bib56"><label>50</label><element-citation publication-type="book" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Yhee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Son</surname><given-names>S.</given-names></name><name name-style="western"><surname>Son</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joo</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>I.C.</given-names></name></person-group><part-title>The EPR effect in cancer therapy</part-title><source>Cancer Targeted Drug Delivery</source><year>2013</year><publisher-name>Springer</publisher-name><fpage>621</fpage><lpage>632</lpage></element-citation></ref><ref id="bib57"><label>51</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Torchilin</surname><given-names>V.</given-names></name></person-group><article-title>Tumor delivery of macromolecular drugs based on the EPR effect</article-title><source>Adv. Drug Deliv. Rev.</source><volume>63</volume><year>2011</year><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">20304019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2010.03.011</pub-id></element-citation></ref><ref id="bib58"><label>52</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Moghimi</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>J.C.</given-names></name></person-group><article-title>Long-circulating and target-specific nanoparticles: theory to practice</article-title><source>Pharmacol. Rev.</source><volume>53</volume><year>2001</year><fpage>283</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">11356986</pub-id></element-citation></ref><ref id="bib59"><label>53</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Brigger</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dubernet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Couvreur</surname><given-names>P.</given-names></name></person-group><article-title>Nanoparticles in cancer therapy and diagnosis</article-title><source>Adv. Drug Deliv. Rev.</source><volume>64</volume><year>2012</year><fpage>24</fpage><lpage>36</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(02)00044-3</pub-id><pub-id pub-id-type="pmid">12204596</pub-id></element-citation></ref><ref id="bib60"><label>54</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Elzoghby</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Samy</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Elgindy</surname><given-names>N.A.</given-names></name></person-group><article-title>Albumin-based nanoparticles as potential controlled release drug delivery systems</article-title><source>J.&#160;Contr. Release</source><volume>157</volume><year>2012</year><fpage>168</fpage><lpage>182</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2011.07.031</pub-id><pub-id pub-id-type="pmid">21839127</pub-id></element-citation></ref><ref id="bib61"><label>55</label><element-citation publication-type="book" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>V Pathak</surname><given-names>Y.</given-names></name></person-group><part-title>Surface Modification of Nanoparticles for Targeted Drug Delivery</part-title><year>2019</year><publisher-name>Springer</publisher-name></element-citation></ref><ref id="bib62"><label>56</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>A.</given-names></name></person-group><article-title>Nanotechnology-based antiviral therapeutics</article-title><source>Drug Deliv. Transl. Res.</source><volume>11</volume><year>2021</year><fpage>748</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">32748035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13346-020-00818-0</pub-id><pub-id pub-id-type="pmcid">PMC7398286</pub-id></element-citation></ref><ref id="bib63"><label>57</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Gurunathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qasim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Do</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name></person-group><article-title>Antiviral potential of nanoparticles&#8212;can nanoparticles fight against coronaviruses?</article-title><source>Nanomaterials</source><volume>10</volume><year>2020</year><fpage>1645</fpage><pub-id pub-id-type="pmid">32825737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano10091645</pub-id><pub-id pub-id-type="pmcid">PMC7557932</pub-id></element-citation></ref><ref id="bib64"><label>58</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Zazo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Colino</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Lanao</surname><given-names>J.M.</given-names></name></person-group><article-title>Current applications of nanoparticles in infectious diseases</article-title><source>J.&#160;Contr. Release</source><volume>224</volume><year>2016</year><fpage>86</fpage><lpage>102</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2016.01.008</pub-id><pub-id pub-id-type="pmid">26772877</pub-id></element-citation></ref><ref id="bib65"><label>59</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Dargazangy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alexander-Katz</surname><given-names>A.</given-names></name></person-group><article-title>Understanding the synergistic effect of physicochemical properties of nanoparticles and their cellular entry pathways</article-title><source>Commun. Biol.</source><volume>3</volume><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">32355216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-020-0917-1</pub-id><pub-id pub-id-type="pmcid">PMC7192949</pub-id></element-citation></ref><ref id="bib66"><label>60</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name></person-group><article-title>An overview of functional nanoparticles as novel emerging antiviral therapeutic agents</article-title><source>Mater. Sci. Eng. C</source><volume>112</volume><year>2020</year><object-id pub-id-type="publisher-id">110924</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msec.2020.110924</pub-id><pub-id pub-id-type="pmcid">PMC7195146</pub-id><pub-id pub-id-type="pmid">32409074</pub-id></element-citation></ref><ref id="bib67"><label>61</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Emery</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Erdman</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Newton</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Winchell</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Holloway</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>McCaustland</surname><given-names>K.A.</given-names></name></person-group><article-title>Real-time reverse transcription&#8211;polymerase chain reaction assay for SARS-associated coronavirus</article-title><source>Emerg. Infect. Dis.</source><volume>10</volume><year>2004</year><fpage>311</fpage><pub-id pub-id-type="pmid">15030703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1002.030759</pub-id><pub-id pub-id-type="pmcid">PMC3322901</pub-id></element-citation></ref><ref id="bib68"><label>62</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Jindal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gopinath</surname><given-names>P.</given-names></name></person-group><article-title>Nanotechnology based approaches for combatting COVID-19 viral infection</article-title><source>Nano Express</source><volume>1</volume><year>2020</year><object-id pub-id-type="publisher-id">22003</object-id></element-citation></ref><ref id="bib69"><label>63</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Mokhtarzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eivazzadeh-Keihan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pashazadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hejazi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gharaatifar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hasanzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>B.</given-names></name><name name-style="western"><surname>de la Guardia</surname><given-names>M.</given-names></name></person-group><article-title>Nanomaterial-based biosensors for detection of pathogenic virus</article-title><source>TrAC, Trends Anal. Chem.</source><volume>97</volume><year>2017</year><fpage>445</fpage><lpage>457</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trac.2017.10.005</pub-id><pub-id pub-id-type="pmcid">PMC7126209</pub-id><pub-id pub-id-type="pmid">32287543</pub-id></element-citation></ref><ref id="bib70"><label>64</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Naresh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>N.</given-names></name></person-group><article-title>A&#160;review on biosensors and recent development of nanostructured materials-enabled biosensors</article-title><source>Sensors</source><volume>21</volume><year>2021</year><fpage>1109</fpage><pub-id pub-id-type="pmid">33562639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s21041109</pub-id><pub-id pub-id-type="pmcid">PMC7915135</pub-id></element-citation></ref><ref id="bib71"><label>65</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kullak-Ublick</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>5268</fpage><lpage>5277</lpage><pub-id pub-id-type="pmid">32281785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c02439</pub-id></element-citation></ref><ref id="bib72"><label>66</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Roh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>S.K.</given-names></name></person-group><article-title>Quantitative and sensitive detection of SARS coronavirus nucleocapsid protein using quantum dots-conjugated RNA aptamer on chip</article-title><source>J.&#160;Chem. Technol. Biotechnol.</source><volume>86</volume><year>2011</year><fpage>1475</fpage><lpage>1479</lpage><pub-id pub-id-type="pmid">32336860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jctb.2721</pub-id><pub-id pub-id-type="pmcid">PMC7167159</pub-id></element-citation></ref><ref id="bib73"><label>67</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Mokhtarzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eivazzadeh-Keihan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pashazadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hejazi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gharaatifar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hasanzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>B.</given-names></name><name name-style="western"><surname>de la Guardia</surname><given-names>M.</given-names></name></person-group><article-title>Nanomaterial-based biosensors for detection of pathogenic virus</article-title><source>TrAC, Trends Anal. Chem.</source><volume>97</volume><year>2017</year><fpage>445</fpage><lpage>457</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trac.2017.10.005</pub-id><pub-id pub-id-type="pmcid">PMC7126209</pub-id><pub-id pub-id-type="pmid">32287543</pub-id></element-citation></ref><ref id="bib74"><label>68</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>D.-R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M.</given-names></name></person-group><article-title>Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles</article-title><source>ACS Sens.</source><volume>4</volume><year>2019</year><fpage>1306</fpage><lpage>1312</lpage><pub-id pub-id-type="pmid">31062580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acssensors.9b00175</pub-id></element-citation></ref><ref id="bib75"><label>69</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.-B.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name></person-group><article-title>Protein nanopatterns and biosensors using gold binding polypeptide as a fusion partner</article-title><source>Anal. Chem.</source><volume>78</volume><year>2006</year><fpage>7197</fpage><lpage>7205</lpage><pub-id pub-id-type="pmid">17037921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ac060976f</pub-id></element-citation></ref><ref id="bib76"><label>70</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neethirajan</surname><given-names>S.</given-names></name></person-group><article-title>Chiral zirconium quantum dots: a new class of nanocrystals for optical detection of coronavirus</article-title><source>Heliyon</source><volume>4</volume><year>2018</year><object-id pub-id-type="publisher-id">e00766</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2018.e00766</pub-id><pub-id pub-id-type="pmcid">PMC6120744</pub-id><pub-id pub-id-type="pmid">30186985</pub-id></element-citation></ref><ref id="bib77"><label>71</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kullak-Ublick</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>5268</fpage><lpage>5277</lpage><pub-id pub-id-type="pmid">32281785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c02439</pub-id></element-citation></ref><ref id="bib78"><label>72</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Layqah</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Eissa</surname><given-names>S.</given-names></name></person-group><article-title>An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes</article-title><source>Microchim. Acta</source><volume>186</volume><year>2019</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00604-019-3345-5</pub-id><pub-id pub-id-type="pmcid">PMC7088225</pub-id><pub-id pub-id-type="pmid">30847572</pub-id></element-citation></ref><ref id="bib79"><label>73</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.-S.</given-names></name><name name-style="western"><surname>Jun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.G.</given-names></name></person-group><article-title>Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>5135</fpage><lpage>5142</lpage><pub-id pub-id-type="pmid">32293168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c02823</pub-id></element-citation></ref><ref id="bib80"><label>74</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>A&#160;new immunochromatographic assay for on-site detection of porcine epidemic diarrhea virus based on monoclonal antibodies prepared by using cell surface fluorescence immunosorbent assay</article-title><source>BMC Vet. Res.</source><volume>15</volume><year>2019</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">30658643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12917-019-1773-4</pub-id><pub-id pub-id-type="pmcid">PMC6339306</pub-id></element-citation></ref><ref id="bib81"><label>75</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Roh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>S.K.</given-names></name></person-group><article-title>Quantitative and sensitive detection of SARS coronavirus nucleocapsid protein using quantum dots-conjugated RNA aptamer on chip</article-title><source>J.&#160;Chem. Technol. Biotechnol.</source><volume>86</volume><year>2011</year><fpage>1475</fpage><lpage>1479</lpage><pub-id pub-id-type="pmid">32336860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jctb.2721</pub-id><pub-id pub-id-type="pmcid">PMC7167159</pub-id></element-citation></ref><ref id="bib82"><label>76</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Mirkin</surname><given-names>C.A.</given-names></name></person-group><article-title>The bio-barcode assay for the detection of protein and nucleic acid targets using DTT-induced ligand exchange</article-title><source>Nat. Protoc.</source><volume>1</volume><year>2006</year><fpage>324</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">17406253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nprot.2006.51</pub-id></element-citation></ref><ref id="bib83"><label>77</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Thaxton</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Elghanian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Stoeva</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Klocker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Horninger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bartsch</surname><given-names>G.</given-names></name></person-group><article-title>Nanoparticle-based bio-barcode assay redefines &#8220;undetectable&#8221; PSA and biochemical recurrence after radical prostatectomy</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>106</volume><year>2009</year><fpage>18437</fpage><lpage>18442</lpage><pub-id pub-id-type="pmid">19841273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0904719106</pub-id><pub-id pub-id-type="pmcid">PMC2773980</pub-id></element-citation></ref><ref id="bib84"><label>78</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Biondi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Feld</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.C.W.</given-names></name></person-group><article-title>Clinical validation of quantum dot barcode diagnostic technology</article-title><source>ACS Nano</source><volume>10</volume><year>2016</year><fpage>4742</fpage><lpage>4753</lpage><pub-id pub-id-type="pmid">27035744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.6b01254</pub-id></element-citation></ref><ref id="bib85"><label>79</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>F.</given-names></name></person-group><article-title>Bio-barcode detection technology and its research applications: a review</article-title><source>J.&#160;Adv. Res.</source><volume>20</volume><year>2019</year><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">31193255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2019.04.009</pub-id><pub-id pub-id-type="pmcid">PMC6522771</pub-id></element-citation></ref><ref id="bib86"><label>80</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>D.-R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M.</given-names></name></person-group><article-title>Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles</article-title><source>ACS Sens.</source><volume>4</volume><year>2019</year><fpage>1306</fpage><lpage>1312</lpage><pub-id pub-id-type="pmid">31062580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acssensors.9b00175</pub-id></element-citation></ref><ref id="bib87"><label>81</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.-B.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name></person-group><article-title>Protein nanopatterns and biosensors using gold binding polypeptide as a fusion partner</article-title><source>Anal. Chem.</source><volume>78</volume><year>2006</year><fpage>7197</fpage><lpage>7205</lpage><pub-id pub-id-type="pmid">17037921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ac060976f</pub-id></element-citation></ref><ref id="bib88"><label>82</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Moitra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alafeef</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dighe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frieman</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name></person-group><article-title>Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>7617</fpage><lpage>7627</lpage><pub-id pub-id-type="pmid">32437124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c03822</pub-id><pub-id pub-id-type="pmcid">PMC7263075</pub-id></element-citation></ref><ref id="bib89"><label>83</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>McClements</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Singla</surname><given-names>P.</given-names></name><name name-style="western"><surname>Canfarotta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Czulak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Crapnell</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>B.</given-names></name></person-group><article-title>Molecularly imprinted polymer nanoparticles enable rapid, reliable, and robust point-of-care thermal detection of SARS-CoV-2</article-title><source>ACS Sens.</source><volume>7</volume><year>2022</year><fpage>1122</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">35416035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acssensors.2c00100</pub-id><pub-id pub-id-type="pmcid">PMC9016778</pub-id></element-citation></ref><ref id="bib90"><label>84</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>McClements</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Singla</surname><given-names>P.</given-names></name><name name-style="western"><surname>Canfarotta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Czulak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Crapnell</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>B.</given-names></name></person-group><article-title>Molecularly imprinted polymer nanoparticles enable rapid, reliable, and robust point-of-care thermal detection of SARS-CoV-2</article-title><source>ACS Sens.</source><volume>7</volume><year>2022</year><fpage>1122</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">35416035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acssensors.2c00100</pub-id><pub-id pub-id-type="pmcid">PMC9016778</pub-id></element-citation></ref><ref id="bib91"><label>85</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Layqah</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Eissa</surname><given-names>S.</given-names></name></person-group><article-title>An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes</article-title><source>Microchim. Acta</source><volume>186</volume><year>2019</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00604-019-3345-5</pub-id><pub-id pub-id-type="pmcid">PMC7088225</pub-id><pub-id pub-id-type="pmid">30847572</pub-id></element-citation></ref><ref id="bib92"><label>86</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.-S.</given-names></name><name name-style="western"><surname>Jun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.G.</given-names></name></person-group><article-title>Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>5135</fpage><lpage>5142</lpage><pub-id pub-id-type="pmid">32293168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c02823</pub-id></element-citation></ref><ref id="bib93"><label>87</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Urban</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jose Valle-Delgado</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moles</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>J.</given-names></name><name name-style="western"><surname>Diez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fernandez-Busquets</surname><given-names>X.</given-names></name></person-group><article-title>Nanotools for the delivery of antimicrobial peptides</article-title><source>Curr. Drug Targets</source><volume>13</volume><year>2012</year><fpage>1158</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">22664075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138945012802002302</pub-id></element-citation></ref><ref id="bib94"><label>88</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Murat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Defrancq</surname><given-names>E.</given-names></name></person-group><article-title>Recent developments in oligonucleotide conjugation</article-title><source>Chem. Soc. Rev.</source><volume>39</volume><year>2010</year><fpage>2054</fpage><lpage>2070</lpage><pub-id pub-id-type="pmid">20393645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/b911431a</pub-id></element-citation></ref><ref id="bib95"><label>89</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Juliano</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Ming</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>O.</given-names></name></person-group><article-title>The chemistry and biology of oligonucleotide conjugates</article-title><source>Acc. Chem. Res.</source><volume>45</volume><year>2012</year><fpage>1067</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">22353142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ar2002123</pub-id><pub-id pub-id-type="pmcid">PMC3374910</pub-id></element-citation></ref><ref id="bib96"><label>90</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name></person-group><article-title>Evaluation of enzyme-linked immunoassay and colloidal gold-immunochromatographic assay kit for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19)</article-title><source>MedRxiv</source><year>2020</year></element-citation></ref><ref id="bib97"><label>91</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Biondi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Feld</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.C.W.</given-names></name></person-group><article-title>Clinical validation of quantum dot barcode diagnostic technology</article-title><source>ACS Nano</source><volume>10</volume><year>2016</year><fpage>4742</fpage><lpage>4753</lpage><pub-id pub-id-type="pmid">27035744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.6b01254</pub-id></element-citation></ref><ref id="bib98"><label>92</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>F.</given-names></name></person-group><article-title>Bio-barcode detection technology and its research applications: a review</article-title><source>J.&#160;Adv. Res.</source><volume>20</volume><year>2019</year><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">31193255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2019.04.009</pub-id><pub-id pub-id-type="pmcid">PMC6522771</pub-id></element-citation></ref><ref id="bib99"><label>93</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Thaxton</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Elghanian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Stoeva</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Klocker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Horninger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bartsch</surname><given-names>G.</given-names></name></person-group><article-title>Nanoparticle-based bio-barcode assay redefines &#8220;undetectable&#8221; PSA and biochemical recurrence after radical prostatectomy</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>106</volume><year>2009</year><fpage>18437</fpage><lpage>18442</lpage><pub-id pub-id-type="pmid">19841273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0904719106</pub-id><pub-id pub-id-type="pmcid">PMC2773980</pub-id></element-citation></ref><ref id="bib100"><label>94</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Mirkin</surname><given-names>C.A.</given-names></name></person-group><article-title>The bio-barcode assay for the detection of protein and nucleic acid targets using DTT-induced ligand exchange</article-title><source>Nat. Protoc.</source><volume>1</volume><year>2006</year><fpage>324</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">17406253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nprot.2006.51</pub-id></element-citation></ref><ref id="bib101"><label>95</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Teengam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Siangproh</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tuantranont</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vilaivan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chailapakul</surname><given-names>O.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>C.S.</given-names></name></person-group><article-title>Multiplex paper-based colorimetric DNA sensor using pyrrolidinyl peptide nucleic acid-induced AgNPs aggregation for detecting MERS-CoV, MTB, and HPV oligonucleotides</article-title><source>Anal. Chem.</source><volume>89</volume><year>2017</year><fpage>5428</fpage><lpage>5435</lpage><pub-id pub-id-type="pmid">28394582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.analchem.7b00255</pub-id><pub-id pub-id-type="pmcid">PMC7077925</pub-id></element-citation></ref><ref id="bib102"><label>96</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Paredes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Garc&#237;a</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Costa-Garc&#237;a</surname><given-names>A.</given-names></name></person-group><article-title>Genosensor for SARS virus detection based on gold nanostructured screen-printed carbon electrodes</article-title><source>Electroanal. Int. J. Devot. Fundament. Pract. Aspects Electroanal.</source><volume>21</volume><year>2009</year><fpage>379</fpage><lpage>385</lpage></element-citation></ref><ref id="bib103"><label>97</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Witika</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Makoni</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Mweetwa</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>V Ntemi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chikukwa</surname><given-names>M.T.R.</given-names></name><name name-style="western"><surname>Matafwali</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Mwila</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mudenda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Katandula</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>R.B.</given-names></name></person-group><article-title>Nano-biomimetic drug delivery vehicles: potential approaches for COVID-19 treatment</article-title><source>Molecules</source><volume>25</volume><year>2020</year><fpage>5952</fpage><pub-id pub-id-type="pmid">33339110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules25245952</pub-id><pub-id pub-id-type="pmcid">PMC7765509</pub-id></element-citation></ref><ref id="bib104"><label>98</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Kirtane</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karandikar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Furin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Traverso</surname><given-names>G.</given-names></name></person-group><article-title>Nanotechnology approaches for global infectious diseases</article-title><source>Nat. Nanotechnol.</source><volume>16</volume><year>2021</year><fpage>369</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">33753915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-021-00866-8</pub-id></element-citation></ref><ref id="bib105"><label>99</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>J.S.</given-names></name></person-group><article-title>Materials science approaches in the development of broad-spectrum antiviral therapies</article-title><source>Nat. Mater.</source><volume>19</volume><year>2020</year><fpage>813</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1038/s41563-020-0698-4</pub-id><pub-id pub-id-type="pmid">32427958</pub-id></element-citation></ref><ref id="bib106"><label>100</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carriere</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fusco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Capua</surname><given-names>I.</given-names></name><name name-style="western"><surname>Regla-Nava</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pasquali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>F.</given-names></name><name name-style="western"><surname>Unal</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mattevi</surname><given-names>C.</given-names></name></person-group><article-title>Toward nanotechnology-enabled approaches against the COVID-19 pandemic</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>6383</fpage><lpage>6406</lpage><pub-id pub-id-type="pmid">32519842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c03697</pub-id></element-citation></ref><ref id="bib107"><label>101</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Varahachalam</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Lahooti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chamaneh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bagchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chhibber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bolanos</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N.-Y.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>A.</given-names></name></person-group><article-title>Nanomedicine for the SARS-CoV-2: state-of-the-art and future prospects</article-title><source>Int. J. Nanomed.</source><volume>16</volume><year>2021</year><fpage>539</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S283686</pub-id><pub-id pub-id-type="pmcid">PMC7837559</pub-id><pub-id pub-id-type="pmid">33519200</pub-id></element-citation></ref><ref id="bib108"><label>102</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Umar</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Al-Batty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ashwaq</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sarief</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadique</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sreekumar</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>S.K.</given-names></name></person-group><article-title>Polymeric materials as potential inhibitors against SARS-CoV-2</article-title><source>J.&#160;Polym. Environ.</source><year>2021</year><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10924-021-02272-6</pub-id><pub-id pub-id-type="pmcid">PMC8426594</pub-id><pub-id pub-id-type="pmid">34518763</pub-id></element-citation></ref><ref id="bib109"><label>103</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>de Barros</surname><given-names>A.O. da S.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Dos Reis</surname><given-names>S.R.R.</given-names></name><name name-style="western"><surname>Ricci-Junior</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alencar</surname><given-names>L.M.R.</given-names></name><name name-style="western"><surname>Bellei</surname><given-names>N.C.J.</given-names></name><name name-style="western"><surname>Janini</surname><given-names>L.R.M.</given-names></name><name name-style="western"><surname>Maricato</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Santos-Oliveira</surname><given-names>R.</given-names></name></person-group><article-title>Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect</article-title><source>J.&#160;Nanostruct. Chem.</source><year>2022</year><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40097-022-00476-3</pub-id><pub-id pub-id-type="pmcid">PMC8881703</pub-id><pub-id pub-id-type="pmid">35251554</pub-id></element-citation></ref><ref id="bib110"><label>104</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>McKay</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blakney</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Samnuan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Penn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bouton</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Polra</surname><given-names>K.</given-names></name></person-group><article-title>Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice</article-title><source>Nat. Commun.</source><volume>11</volume><year>2020</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">32647131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17409-9</pub-id><pub-id pub-id-type="pmcid">PMC7347890</pub-id></element-citation></ref><ref id="bib111"><label>105</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Kremsner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fendel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gabor</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kreidenweiss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kroidl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>C.</given-names></name></person-group><article-title>Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers</article-title><source>MedRxiv</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00508-021-01922-y</pub-id><pub-id pub-id-type="pmcid">PMC8354521</pub-id><pub-id pub-id-type="pmid">34378087</pub-id></element-citation></ref><ref id="bib112"><label>106</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Hossain</surname><given-names>S.</given-names></name></person-group><article-title>A&#160;study on understanding potential gold and silver nanoparticle: an overview</article-title><source>Int. J. Nanosci.</source><volume>20</volume><year>2021</year><object-id pub-id-type="publisher-id">2150009</object-id></element-citation></ref><ref id="bib113"><label>107</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Mignani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Karpus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lentini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Majoral</surname><given-names>J.-P.</given-names></name></person-group><article-title>Functionalized dendrimer platforms as a new forefront arsenal targeting SARS-CoV-2: an opportunity</article-title><source>Pharmaceutics</source><volume>13</volume><year>2021</year><fpage>1513</fpage><pub-id pub-id-type="pmid">34575589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13091513</pub-id><pub-id pub-id-type="pmcid">PMC8466088</pub-id></element-citation></ref><ref id="bib114"><label>108</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Sportelli</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Izzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kukushkina</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Picca</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Ditaranto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cioffi</surname><given-names>N.</given-names></name></person-group><article-title>Can nanotechnology and materials science help the fight against SARS-CoV-2?</article-title><source>Nanomaterials</source><volume>10</volume><year>2020</year><fpage>802</fpage><pub-id pub-id-type="pmid">32326343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano10040802</pub-id><pub-id pub-id-type="pmcid">PMC7221591</pub-id></element-citation></ref><ref id="bib115"><label>109</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>W.</given-names></name></person-group><article-title>Insights from nanotechnology in COVID-19 treatment</article-title><source>Nano Today</source><volume>36</volume><year>2021</year><object-id pub-id-type="publisher-id">101019</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nantod.2020.101019</pub-id><pub-id pub-id-type="pmcid">PMC7640897</pub-id><pub-id pub-id-type="pmid">33178330</pub-id></element-citation></ref><ref id="bib116"><label>110</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Solanki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jodha</surname><given-names>B.</given-names></name><name name-style="western"><surname>Prabina</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name></person-group><article-title>Recent advances in phytochemical based nano-drug delivery systems to combat breast cancer: a review</article-title><source>J.&#160;Drug Deliv. Sci. Technol.</source><year>2022</year><object-id pub-id-type="publisher-id">103832</object-id></element-citation></ref><ref id="bib117"><label>111</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Zieli&#324;ska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carreir&#243;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Neves</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>B.</given-names></name><name name-style="western"><surname>Venkatesh</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Durazzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lucarini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.M.</given-names></name></person-group><article-title>Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology</article-title><source>Molecules</source><volume>25</volume><year>2020</year><fpage>3731</fpage><pub-id pub-id-type="pmid">32824172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules25163731</pub-id><pub-id pub-id-type="pmcid">PMC7464532</pub-id></element-citation></ref><ref id="bib118"><label>112</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Solanki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name></person-group><article-title>Bovine serum albumin nanoparticles for the efficient delivery of berberine: preparation, characterization and in&#160;vitro biological studies</article-title><source>Colloids Surf. A Physicochem. Eng. Asp.</source><volume>608</volume><year>2021</year><object-id pub-id-type="publisher-id">125501</object-id></element-citation></ref><ref id="bib119"><label>113</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Jangid</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Solanki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pooja</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kulhari</surname><given-names>H.</given-names></name></person-group><article-title>Genistein encapsulated inulin-stearic acid bioconjugate nanoparticles: formulation development, characterization and anticancer activity</article-title><source>Int. J. Biol. Macromol.</source><volume>206</volume><year>2022</year><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">35181329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2022.02.031</pub-id></element-citation></ref><ref id="bib120"><label>114</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Jangid</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Solanki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Medicherla</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pooja</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kulhari</surname><given-names>H.</given-names></name></person-group><article-title>Improving anticancer activity of Chrysin using tumor microenvironment pH-responsive and self-assembled nanoparticles</article-title><source>ACS Omega</source><volume>7</volume><year>2022</year><fpage>15919</fpage><lpage>15928</lpage><pub-id pub-id-type="pmid">35571829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsomega.2c01041</pub-id><pub-id pub-id-type="pmcid">PMC9096951</pub-id></element-citation></ref><ref id="bib121"><label>115</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Owens</surname><given-names>D.E.</given-names><suffix>III</suffix></name><name name-style="western"><surname>Peppas</surname><given-names>N.A.</given-names></name></person-group><article-title>Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles</article-title><source>Int. J. Pharm.</source><volume>307</volume><year>2006</year><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">16303268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2005.10.010</pub-id></element-citation></ref><ref id="bib122"><label>116</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Soppimath</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Aminabhavi</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Rudzinski</surname><given-names>W.E.</given-names></name></person-group><article-title>Biodegradable polymeric nanoparticles as drug delivery devices</article-title><source>J.&#160;Contr. Release</source><volume>70</volume><year>2001</year><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-3659(00)00339-4</pub-id><pub-id pub-id-type="pmid">11166403</pub-id></element-citation></ref><ref id="bib123"><label>117</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Solanki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rostamabadi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>S.M.</given-names></name></person-group><article-title>Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: a critical review</article-title><source>Int. J. Biol. Macromol.</source><volume>193</volume><year>2021</year><fpage>528</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">34655592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2021.10.040</pub-id></element-citation></ref><ref id="bib124"><label>118</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Iannazzo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pistone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>R.</given-names></name><name name-style="western"><surname>V Giofr&#232;</surname><given-names>S.</given-names></name></person-group><article-title>Nanotechnology approaches for antiretroviral drugs delivery</article-title><source>J.&#160;Aids Hiv. Infect.</source><volume>1</volume><year>2015</year><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="bib125"><label>119</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Puryear</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Seifried</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Runstadler</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ribbeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>B.D.</given-names></name></person-group><article-title>Antiviral agents from multivalent presentation of sialyl oligosaccharides on brush polymers</article-title><source>ACS Macro Lett.</source><volume>5</volume><year>2016</year><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">35614714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsmacrolett.5b00917</pub-id></element-citation></ref><ref id="bib126"><label>120</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>A.</given-names></name></person-group><article-title>Nanotechnology-based antiviral therapeutics</article-title><source>Drug Deliv. Transl. Res.</source><volume>11</volume><year>2021</year><fpage>748</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">32748035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13346-020-00818-0</pub-id><pub-id pub-id-type="pmcid">PMC7398286</pub-id></element-citation></ref><ref id="bib127"><label>121</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Mallipeddi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rohan</surname><given-names>L.C.</given-names></name></person-group><article-title>Progress in antiretroviral drug delivery using nanotechnology</article-title><source>Int. J. Nanomed.</source><volume>5</volume><year>2010</year><fpage>533</fpage><pub-id pub-id-type="pmcid">PMC2950411</pub-id><pub-id pub-id-type="pmid">20957115</pub-id></element-citation></ref><ref id="bib128"><label>122</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Spirescu</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Chircov</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grumezescu</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Andronescu</surname><given-names>E.</given-names></name></person-group><article-title>Polymeric nanoparticles for antimicrobial therapies: an up-to-date overview</article-title><source>Polymers (Basel)</source><volume>13</volume><year>2021</year><fpage>724</fpage><pub-id pub-id-type="pmid">33673451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/polym13050724</pub-id><pub-id pub-id-type="pmcid">PMC7956825</pub-id></element-citation></ref><ref id="bib129"><label>123</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Alizadeh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Khodavandi</surname><given-names>A.</given-names></name></person-group><article-title>Systematic review and meta-analysis of the efficacy of nanoscale materials against coronaviruses&#8212;possible potential antiviral agents for SARS-CoV-2</article-title><source>IEEE Trans. NanoBioscience</source><volume>19</volume><year>2020</year><fpage>485</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">32603297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TNB.2020.2997257</pub-id></element-citation></ref><ref id="bib130"><label>124</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.-Y.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>D.-W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-M.</given-names></name></person-group><article-title>Heterologous prime&#8211;boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus</article-title><source>Vaccine</source><volume>36</volume><year>2018</year><fpage>3468</fpage><lpage>3476</lpage><pub-id pub-id-type="pmid">29739720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.04.082</pub-id><pub-id pub-id-type="pmcid">PMC7115429</pub-id></element-citation></ref><ref id="bib131"><label>125</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Santenna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vidyasagar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amarneni</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Ghanta</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Sadasivam</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Padmavathi</surname><given-names>R.</given-names></name></person-group><article-title>The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis</article-title><source>Ther. Adv. Drug Saf.</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">20420986211042516</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20420986211042517</pub-id><pub-id pub-id-type="pmcid">PMC8477695</pub-id><pub-id pub-id-type="pmid">34594487</pub-id></element-citation></ref><ref id="bib132"><label>126</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name></person-group><article-title>Structure-aided ACEI-capped remdesivir-loaded novel PLGA nanoparticles: toward a computational simulation design for anti-SARS-CoV-2 therapy</article-title><source>Phys. Chem. Chem. Phys.</source><volume>22</volume><year>2020</year><fpage>28434</fpage><lpage>28439</lpage><pub-id pub-id-type="pmid">33305304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0cp04389c</pub-id></element-citation></ref><ref id="bib133"><label>127</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Gautret</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lagier</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Parola</surname><given-names>P.</given-names></name><name name-style="western"><surname>Meddeb</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mailhe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doudier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Courjon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Giordanengo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vieira</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>H.T.</given-names></name></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int. J. Antimicrob. Agents</source><volume>56</volume><year>2020</year><object-id pub-id-type="publisher-id">105949</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2020.105949</pub-id><pub-id pub-id-type="pmcid">PMC7102549</pub-id><pub-id pub-id-type="pmid">32205204</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11718083"/></element-citation></ref><ref id="bib134"><label>128</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>de Barros</surname><given-names>A.O. da S.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Dos Reis</surname><given-names>S.R.R.</given-names></name><name name-style="western"><surname>Ricci-Junior</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alencar</surname><given-names>L.M.R.</given-names></name><name name-style="western"><surname>Bellei</surname><given-names>N.C.J.</given-names></name><name name-style="western"><surname>Janini</surname><given-names>L.R.M.</given-names></name><name name-style="western"><surname>Maricato</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Santos-Oliveira</surname><given-names>R.</given-names></name></person-group><article-title>Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect</article-title><source>J.&#160;Nanostruct. Chem.</source><year>2022</year><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40097-022-00476-3</pub-id><pub-id pub-id-type="pmcid">PMC8881703</pub-id><pub-id pub-id-type="pmid">35251554</pub-id></element-citation></ref><ref id="bib135"><label>129</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Arshad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kilgore</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chaudhry</surname><given-names>Z.S.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Huitsing</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alangaden</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>McKinnon</surname><given-names>J.E.</given-names></name></person-group><article-title>Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19</article-title><source>Int. J. Infect. Dis.</source><volume>97</volume><year>2020</year><fpage>396</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">32623082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2020.06.099</pub-id><pub-id pub-id-type="pmcid">PMC7330574</pub-id></element-citation></ref><ref id="bib136"><label>130</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Caly</surname><given-names>L.</given-names></name><name name-style="western"><surname>Druce</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Catton</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Jans</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Wagstaff</surname><given-names>K.M.</given-names></name></person-group><article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in&#160;vitro</article-title><source>Antivir. Res.</source><volume>178</volume><year>2020</year><object-id pub-id-type="publisher-id">104787</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2020.104787</pub-id><pub-id pub-id-type="pmcid">PMC7129059</pub-id><pub-id pub-id-type="pmid">32251768</pub-id></element-citation></ref><ref id="bib137"><label>131</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Surnar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kamran</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>U.</given-names></name><name name-style="western"><surname>Kolishetti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Deo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jayaweera</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Daunert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group><article-title>Orally administrable therapeutic synthetic nanoparticle for Zika virus</article-title><source>ACS Nano</source><volume>13</volume><year>2019</year><fpage>11034</fpage><lpage>11048</lpage><pub-id pub-id-type="pmid">31603314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.9b02807</pub-id><pub-id pub-id-type="pmcid">PMC7053157</pub-id></element-citation></ref><ref id="bib138"><label>132</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Sanna</surname><given-names>V.</given-names></name><name name-style="western"><surname>Satta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hsiai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sechi</surname><given-names>M.</given-names></name></person-group><article-title>Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition</article-title><source>Eur. J. Med. Chem.</source><volume>231</volume><year>2022</year><object-id pub-id-type="publisher-id">114121</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2022.114121</pub-id><pub-id pub-id-type="pmcid">PMC8755562</pub-id><pub-id pub-id-type="pmid">35114539</pub-id></element-citation></ref><ref id="bib139"><label>133</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Frieman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wolfram</surname><given-names>J.</given-names></name></person-group><article-title>Insights from nanomedicine into chloroquine efficacy against COVID-19</article-title><source>Nat. Nanotechnol.</source><volume>15</volume><year>2020</year><fpage>247</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">32203437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-020-0674-9</pub-id><pub-id pub-id-type="pmcid">PMC7094976</pub-id></element-citation></ref><ref id="bib140"><label>134</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Group</surname><given-names>T.R.C.</given-names></name></person-group><article-title>Dexamethasone in hospitalized patients with Covid-19&#8212;preliminary report</article-title><source>N.&#160;Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2021436</pub-id><pub-id pub-id-type="pmcid">PMC7383595</pub-id><pub-id pub-id-type="pmid">32678530</pub-id></element-citation></ref><ref id="bib141"><label>135</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Varahachalam</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Lahooti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chamaneh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bagchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chhibber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bolanos</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N.-Y.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>A.</given-names></name></person-group><article-title>Nanomedicine for the SARS-CoV-2: state-of-the-art and future prospects</article-title><source>Int. J. Nanomed.</source><volume>16</volume><year>2021</year><fpage>539</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S283686</pub-id><pub-id pub-id-type="pmcid">PMC7837559</pub-id><pub-id pub-id-type="pmid">33519200</pub-id></element-citation></ref><ref id="bib142"><label>136</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Kamat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jayabaskaran</surname><given-names>C.</given-names></name></person-group><article-title>Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2</article-title><source>J.&#160;Contr. Release</source><volume>338</volume><year>2021</year><fpage>813</fpage><lpage>836</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2021.08.046</pub-id><pub-id pub-id-type="pmcid">PMC8406542</pub-id><pub-id pub-id-type="pmid">34478750</pub-id></element-citation></ref><ref id="bib143"><label>137</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Neufurth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tolba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lieberwirth</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schr&#246;der</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>W.E.G.</given-names></name></person-group><article-title>The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations</article-title><source>Biochem. Pharmacol.</source><volume>182</volume><year>2020</year><object-id pub-id-type="publisher-id">114215</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2020.114215</pub-id><pub-id pub-id-type="pmcid">PMC7474874</pub-id><pub-id pub-id-type="pmid">32905794</pub-id></element-citation></ref><ref id="bib144"><label>138</label><element-citation publication-type="journal" id="sref144"><article-title>Lasting impact of lipid nanoparticles</article-title><source>Nat. Rev. Mater.</source><volume>6</volume><year>2021</year><fpage>1071</fpage><pub-id pub-id-type="doi">10.1038/s41578-021-00398-6</pub-id></element-citation></ref><ref id="bib145"><label>139</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>Y.N.</given-names></name></person-group><article-title>BNT162b2 mRNA COVID-19 vaccine: first approval</article-title><source>Drugs</source><volume>81</volume><year>2021</year><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">33683637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-021-01480-7</pub-id><pub-id pub-id-type="pmcid">PMC7938284</pub-id></element-citation></ref><ref id="bib146"><label>140</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name></person-group><article-title>Lipid nanoparticles for mRNA delivery</article-title><source>Nat. Rev. Mater.</source><volume>6</volume><year>2021</year><fpage>1078</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">34394960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41578-021-00358-0</pub-id><pub-id pub-id-type="pmcid">PMC8353930</pub-id></element-citation></ref><ref id="bib147"><label>141</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Karnik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Basto</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cannizzaro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kyei-Manu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Farokhzad</surname><given-names>O.C.</given-names></name></person-group><article-title>Microfluidic platform for controlled synthesis of polymeric nanoparticles</article-title><source>Nano Lett.</source><volume>8</volume><year>2008</year><fpage>2906</fpage><lpage>2912</lpage><pub-id pub-id-type="pmid">18656990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nl801736q</pub-id></element-citation></ref><ref id="bib148"><label>142</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eygeris</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sahay</surname><given-names>G.</given-names></name></person-group><article-title>Self-assembled mRNA vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><volume>170</volume><year>2021</year><fpage>83</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">33400957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2020.12.014</pub-id><pub-id pub-id-type="pmcid">PMC7837307</pub-id></element-citation></ref><ref id="bib149"><label>143</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Kranz</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kreiter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loquai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vascotto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hefesha</surname><given-names>H.</given-names></name></person-group><article-title>Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy</article-title><source>Nature</source><volume>534</volume><year>2016</year><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">27281205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature18300</pub-id></element-citation></ref><ref id="bib151"><label>144</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Use of siRNAs to prevent and treat influenza virus infection</article-title><source>Virus Res.</source><volume>102</volume><year>2004</year><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15068878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virusres.2004.01.013</pub-id></element-citation></ref><ref id="bib152"><label>145</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Bitko</surname><given-names>V.</given-names></name><name name-style="western"><surname>Musiyenko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shulyayeva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Barik</surname><given-names>S.</given-names></name></person-group><article-title>Inhibition of respiratory viruses by nasally administered siRNA</article-title><source>Nat. Med.</source><volume>11</volume><year>2005</year><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">15619632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1164</pub-id></element-citation></ref><ref id="bib153"><label>146</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Jamali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mottaghitalab</surname><given-names>F.</given-names></name><name name-style="western"><surname>Abdoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dinarvand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esmailie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kheiri</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Atyabi</surname><given-names>F.</given-names></name></person-group><article-title>Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA</article-title><source>Drug Deliv. Transl. Res.</source><volume>8</volume><year>2018</year><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">29063498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13346-017-0426-z</pub-id></element-citation></ref><ref id="bib150"><label>147</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Ullah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Qazi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kanaras</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>A.</given-names></name></person-group><article-title>Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: a candidate approach against SARS-COV-2</article-title><source>Nano Sel.</source><volume>1</volume><year>2020</year><fpage>612</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">34485978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/nano.202000125</pub-id><pub-id pub-id-type="pmcid">PMC7675679</pub-id></element-citation></ref><ref id="bib154"><label>148</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Tavakoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ataei-Pirkooh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mm Sadeghi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bokharaei-Salim</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sahrapour</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kiani</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Moghoofei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farahmand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Javanmard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Monavari</surname><given-names>S.H.</given-names></name></person-group><article-title>Polyethylene glycol-coated zinc oxide nanoparticle: an efficient nanoweapon to fight against herpes simplex virus type 1</article-title><source>Nanomedicine</source><volume>13</volume><year>2018</year><fpage>2675</fpage><lpage>2690</lpage><pub-id pub-id-type="pmid">30346253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/nnm-2018-0089</pub-id></element-citation></ref><ref id="bib155"><label>149</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Alimardani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Abolmaali</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Tamaddon</surname><given-names>A.M.</given-names></name></person-group><article-title>Recent advances on nanotechnology-based strategies for prevention, diagnosis, and treatment of coronavirus infections</article-title><source>J.&#160;Nanomater.</source><volume>2021</volume><year>2021</year><fpage>1</fpage><lpage>20</lpage></element-citation></ref><ref id="bib156"><label>150</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>Tavakol</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zahmatkeshan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohammadinejad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mehrzadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joghataei</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Alavijeh</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Seifalian</surname><given-names>A.</given-names></name></person-group><article-title>The role of nanotechnology in current COVID-19 outbreak</article-title><source>Heliyon</source><volume>7</volume><year>2021</year><object-id pub-id-type="publisher-id">e06841</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2021.e06841</pub-id><pub-id pub-id-type="pmcid">PMC8049405</pub-id><pub-id pub-id-type="pmid">33880422</pub-id></element-citation></ref><ref id="bib157"><label>151</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Medhi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Srinoi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>H.-V.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.R.</given-names></name></person-group><article-title>Nanoparticle-based strategies to combat COVID-19</article-title><source>ACS Appl. Nano Mater.</source><volume>3</volume><year>2020</year><fpage>8557</fpage><lpage>8580</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsanm.0c01978</pub-id><pub-id pub-id-type="pmid">37556239</pub-id></element-citation></ref><ref id="bib158"><label>152</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Damasco</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ravi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Hagaman</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Melancon</surname><given-names>M.P.</given-names></name></person-group><article-title>Understanding nanoparticle toxicity to direct a safe-by-design approach in cancer nanomedicine</article-title><source>Nanomaterials</source><volume>10</volume><year>2020</year><fpage>2186</fpage><pub-id pub-id-type="pmid">33147800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano10112186</pub-id><pub-id pub-id-type="pmcid">PMC7692849</pub-id></element-citation></ref><ref id="bib159"><label>153</label><element-citation publication-type="book" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Bertagnolio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thwin</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>N.</given-names></name><name name-style="western"><surname>Baggaley</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vitoria</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jassat</surname><given-names>W.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>J.</given-names></name></person-group><part-title>Clinical Features and Prognostic Factors of COVID-19 in People Living with HIV Hospitalized with Suspected or Confirmed SARS-CoV-2 Infection</part-title><source>11th IAS Conference on HIV Science</source><year>2021</year><comment>abstract PEBLB20</comment></element-citation></ref><ref id="bib160"><label>154</label><element-citation publication-type="book" id="sref160"><person-group person-group-type="author"><collab>WHO</collab></person-group><part-title>Clinical Care Severe Acute Respiratory Infection. Toolkit.</part-title><year>2020</year><publisher-name>WHO Technical Report Series.</publisher-name><fpage>196</fpage></element-citation></ref><ref id="bib161"><label>155</label><element-citation publication-type="book" id="sref161"><person-group person-group-type="author"><collab>WHO</collab></person-group><part-title>Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim Guidance 21</part-title><source>Triage: Early Recognition of Patients with SARI Associated with nCoV Infection</source><year>2020</year><fpage>1</fpage><lpage>2</lpage></element-citation></ref><ref id="bib162"><label>156</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><collab>E. Diseases</collab></person-group><article-title>WHO guidelines</article-title><source>Med. Today</source><volume>2</volume><year>2001</year><fpage>7</fpage></element-citation></ref><ref id="bib163"><label>157</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Kickbusch</surname><given-names>I.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>G.</given-names></name><name name-style="western"><surname>Briand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mounts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chamberland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dunlop</surname><given-names>C.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>World Health Organization</surname><given-names>W.</given-names></name><name name-style="western"><surname>Relations</surname><given-names>F.</given-names></name><name name-style="western"><surname>Affairs</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kupferschmidt</surname><given-names>K.</given-names></name><collab>WHO, 2016</collab><name name-style="western"><surname>Nurarif</surname></name><name name-style="western"><surname>Kusuma</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Long</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ehrenfeld</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Balicer</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Omer</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Everly</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>L.O.</given-names></name><name name-style="western"><surname>Gostin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Riou</surname><given-names>C.L.</given-names></name></person-group><article-title>Althaus, WHO R&amp;D Blueprint Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection</article-title><source>Euro Surveill.</source><volume>25</volume><year>2020</year><fpage>709</fpage><lpage>710</lpage></element-citation></ref><ref id="bib164"><label>158</label><element-citation publication-type="book" id="sref164"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><part-title>WHO Therapeutics and COVID-19 Living guideline</part-title><edition>tenth ed.</edition><year>2022</year><publisher-name>World Health Organisation</publisher-name><fpage>128</fpage></element-citation></ref><ref id="bib165"><label>159</label><mixed-citation publication-type="other" id="sref165">W.H.O. Covid-, L. Clinical, M. Guidance, W.H.O.L. Guidelines, Who Covid-19 Clinical Care Bundle, (n.d.).</mixed-citation></ref><ref id="bib166"><label>160</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>N.H.L.</given-names></name></person-group><article-title>Transmissibility and transmission of respiratory viruses</article-title><source>Nat. Rev. Microbiol.</source><volume>19</volume><year>2021</year><fpage>528</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00535-6</pub-id><pub-id pub-id-type="pmid">33753932</pub-id><pub-id pub-id-type="pmcid">PMC7982882</pub-id></element-citation></ref><ref id="bib167"><label>161</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Wiersinga</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>H.C.</given-names></name></person-group><article-title>Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review</article-title><source>JAMA</source><volume>324</volume><year>2020</year><fpage>782</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.12839</pub-id><pub-id pub-id-type="pmid">32648899</pub-id></element-citation></ref><ref id="bib168"><label>162</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Shaukat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Razzak</surname><given-names>J.</given-names></name></person-group><article-title>Physical and mental health impacts of COVID-19 on healthcare workers: a scoping review</article-title><source>Int. J. Emerg. Med.</source><volume>13</volume><year>2020</year><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s12245-020-00299-5</pub-id><pub-id pub-id-type="pmid">32689925</pub-id><pub-id pub-id-type="pmcid">PMC7370263</pub-id></element-citation></ref><ref id="bib169"><label>163</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Azuma</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yanagi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Kagi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ogata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>M.</given-names></name></person-group><article-title>Environmental factors involved in SARS-CoV-2 transmission: effect and role of indoor environmental quality in the strategy for COVID-19 infection control</article-title><source>Environ. Health Prev. Med.</source><volume>25</volume><year>2020</year><fpage>66</fpage><pub-id pub-id-type="doi">10.1186/s12199-020-00904-2</pub-id><pub-id pub-id-type="pmid">33143660</pub-id><pub-id pub-id-type="pmcid">PMC7607900</pub-id></element-citation></ref><ref id="bib170"><label>164</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carriere</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fusco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Capua</surname><given-names>I.</given-names></name><name name-style="western"><surname>Regla-Nava</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pasquali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>F.</given-names></name><name name-style="western"><surname>Unal</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mattevi</surname><given-names>C.</given-names></name></person-group><article-title>Toward nanotechnology-enabled approaches against the COVID-19 pandemic</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>6383</fpage><lpage>6406</lpage><pub-id pub-id-type="pmid">32519842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c03697</pub-id></element-citation></ref><ref id="bib171"><label>165</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>Yayehrad</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Siraj</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Wondie</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Alemie</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Derseh</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Ambaye</surname><given-names>A.S.</given-names></name></person-group><article-title>Could nanotechnology help to end the fight against COVID-19? Review of current findings, challenges and future perspectives</article-title><source>Int. J. Nanomed.</source><volume>16</volume><year>2021</year><fpage>5713</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S327334</pub-id><pub-id pub-id-type="pmcid">PMC8402990</pub-id><pub-id pub-id-type="pmid">34465991</pub-id></element-citation></ref><ref id="bib172"><label>166</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pirzada</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Price</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shibiru</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Qurashi</surname><given-names>A.</given-names></name></person-group><article-title>Applications of nanotechnology in smart textile industry: a critical review</article-title><source>J.&#160;Adv. Res.</source><volume>38</volume><year>2022</year><fpage>55</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">35572402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2022.01.008</pub-id><pub-id pub-id-type="pmcid">PMC9091772</pub-id></element-citation></ref><ref id="bib173"><label>167</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>El-Atab</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>M.M.</given-names></name></person-group><article-title>Toward nanotechnology-enabled face masks against SARS-CoV-2 and pandemic respiratory diseases</article-title><source>Nanotechnology</source><volume>33</volume><year>2021</year><object-id pub-id-type="publisher-id">62006</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1088/1361-6528/ac3578</pub-id><pub-id pub-id-type="pmid">34727530</pub-id></element-citation></ref><ref id="bib174"><label>168</label><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name name-style="western"><surname>Emam</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Rehan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mashaly</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>H.B.</given-names></name></person-group><article-title>Large scaled strategy for natural/synthetic fabrics functionalization via immediate assembly of AgNPs</article-title><source>Dyes Pigments</source><volume>133</volume><year>2016</year><fpage>173</fpage><lpage>183</lpage></element-citation></ref><ref id="bib175"><label>169</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Velmurugan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>B.-T.</given-names></name></person-group><article-title>Antimicrobial fabrication of cotton fabric and leather using green-synthesized nanosilver</article-title><source>Carbohydr. Polym.</source><volume>106</volume><year>2014</year><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">24721085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carbpol.2014.02.021</pub-id></element-citation></ref><ref id="bib176"><label>170</label><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name></person-group><article-title>Silver-nanoparticle-colored cotton fabrics with tunable colors and durable antibacterial and self-healing superhydrophobic properties</article-title><source>Adv. Funct. Mater.</source><volume>26</volume><year>2016</year><fpage>569</fpage><lpage>576</lpage></element-citation></ref><ref id="bib177"><label>171</label><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name name-style="western"><surname>Salleh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naomi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Utami</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Mahmoudi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fauzi</surname><given-names>M.B.</given-names></name></person-group><article-title>The potential of silver nanoparticles for antiviral and antibacterial applications: a mechanism of action</article-title><source>Nanomaterials</source><volume>10</volume><year>2020</year><fpage>1566</fpage><pub-id pub-id-type="pmid">32784939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano10081566</pub-id><pub-id pub-id-type="pmcid">PMC7466543</pub-id></element-citation></ref><ref id="bib178"><label>172</label><element-citation publication-type="journal" id="sref178"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chughtai</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Macintyre</surname><given-names>C.R.</given-names></name></person-group><article-title>Graphene modified multifunctional personal protective clothing</article-title><source>Adv. Mater. Interfac.</source><volume>6</volume><year>2019</year><object-id pub-id-type="publisher-id">1900622</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/admi.201900622</pub-id><pub-id pub-id-type="pmcid">PMC7161773</pub-id><pub-id pub-id-type="pmid">32313805</pub-id></element-citation></ref><ref id="bib179"><label>173</label><element-citation publication-type="journal" id="sref179"><person-group person-group-type="author"><name name-style="western"><surname>Papaspyrides</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Pavlidou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vouyiouka</surname><given-names>S.N.</given-names></name></person-group><article-title>Development of advanced textile materials: natural fibre composites, anti-microbial, and flame-retardant fabrics</article-title><source>Proc. IME J. Mater. Des. Appl.</source><volume>223</volume><year>2009</year><fpage>91</fpage><lpage>102</lpage></element-citation></ref><ref id="bib180"><label>174</label><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Collie</surname><given-names>S.</given-names></name></person-group><article-title>Textile sensors for wearable applications: a comprehensive review</article-title><source>Cellulose</source><volume>27</volume><year>2020</year><fpage>6103</fpage><lpage>6131</lpage></element-citation></ref><ref id="bib181"><label>175</label><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>E.V.R.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>A.E.S.</given-names></name><name name-style="western"><surname>De Oliveira</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Guilger-Casagrande</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Lima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fraceto</surname><given-names>L.F.</given-names></name></person-group><article-title>How can nanotechnology help to combat COVID-19? Opportunities and urgent need</article-title><source>J.&#160;Nanobiotechnol.</source><volume>18</volume><year>2020</year><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-020-00685-4</pub-id><pub-id pub-id-type="pmcid">PMC7474329</pub-id><pub-id pub-id-type="pmid">32891146</pub-id></element-citation></ref><ref id="bib182"><label>176</label><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name name-style="western"><surname>Hashmi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alexis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name></person-group><article-title>Potentialities of graphene and its allied derivatives to combat against SARS-CoV-2 infection</article-title><source>Mater Today Adv</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">100208</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mtadv.2022.100208</pub-id><pub-id pub-id-type="pmcid">PMC8755454</pub-id><pub-id pub-id-type="pmid">35039802</pub-id></element-citation></ref><ref id="bib183"><label>177</label><element-citation publication-type="journal" id="sref183"><person-group person-group-type="author"><name name-style="western"><surname>Rai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonde</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhowmik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rathod</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ingle</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gade</surname><given-names>A.</given-names></name></person-group><article-title>Nanotechnology as a shield against COVID-19: current advancement and limitations</article-title><source>Viruses</source><volume>13</volume><year>2021</year><fpage>1224</fpage><pub-id pub-id-type="pmid">34202815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13071224</pub-id><pub-id pub-id-type="pmcid">PMC8310263</pub-id></element-citation></ref><ref id="bib184"><label>178</label><element-citation publication-type="journal" id="sref184"><person-group person-group-type="author"><name name-style="western"><surname>Talebian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stellacci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Conde</surname><given-names>J.</given-names></name></person-group><article-title>Nanotechnology-based disinfectants and sensors for SARS-CoV-2</article-title><source>Nat. Nanotechnol.</source><volume>15</volume><year>2020</year><fpage>618</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">32728083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-020-0751-0</pub-id></element-citation></ref><ref id="bib185"><label>179</label><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name name-style="western"><surname>Byambasuren</surname><given-names>O.</given-names></name><name name-style="western"><surname>Beller</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Glasziou</surname><given-names>P.</given-names></name></person-group><article-title>The effect of eye protection on SARS-CoV-2 transmission: a systematic review</article-title><source>Antimicrob. Resist. Infect. Control</source><volume>10</volume><year>2021</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">34736533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13756-021-01025-3</pub-id><pub-id pub-id-type="pmcid">PMC8567128</pub-id></element-citation></ref><ref id="bib186"><label>180</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Coroneo</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>P.J.</given-names></name></person-group><article-title>SARS-CoV-2: eye protection might be the missing key</article-title><source>Lancet Microbe</source><volume>2</volume><year>2021</year><fpage>e173</fpage><lpage>e174</lpage><pub-id pub-id-type="pmid">33655228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-5247(21)00040-9</pub-id><pub-id pub-id-type="pmcid">PMC7906687</pub-id></element-citation></ref><ref id="bib187"><label>181</label><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name></person-group><article-title>The need for ocular protection for health care workers during SARS-CoV-2 outbreak and a hypothesis for a potential personal protective equipment</article-title><source>Front. Public Health</source><volume>8</volume><year>2020</year><object-id pub-id-type="publisher-id">599757</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2020.599757</pub-id><pub-id pub-id-type="pmcid">PMC7690622</pub-id><pub-id pub-id-type="pmid">33282819</pub-id></element-citation></ref><ref id="bib188"><label>182</label><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name></person-group><article-title>Griffithsin inhibits porcine reproductive and respiratory syndrome virus infection in&#160;vitro</article-title><source>Arch. Virol.</source><volume>163</volume><year>2018</year><fpage>3317</fpage><lpage>3325</lpage><pub-id pub-id-type="pmid">30220033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00705-018-4029-x</pub-id><pub-id pub-id-type="pmcid">PMC7087274</pub-id></element-citation></ref><ref id="bib189"><label>183</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Rundle</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Presley</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Militello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>C.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Atwater</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Watsky</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunnick</surname><given-names>C.A.</given-names></name></person-group><article-title>Hand hygiene during COVID-19: recommendations from the American contact dermatitis society</article-title><source>J.&#160;Am. Acad. Dermatol.</source><volume>83</volume><year>2020</year><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="pmid">32707253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2020.07.057</pub-id><pub-id pub-id-type="pmcid">PMC7373692</pub-id></element-citation></ref><ref id="bib190"><label>184</label><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>V.</given-names></name><name name-style="western"><surname>Royal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chavali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>S.K.</given-names></name></person-group><article-title>Advancements in research and development to combat COVID-19 using nanotechnology</article-title><source>Nanotechnol. Environ. Eng.</source><volume>6</volume><year>2021</year><fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="bib191"><label>185</label><element-citation publication-type="book" id="sref191"><person-group person-group-type="author"><name name-style="western"><surname>Abolmaali</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Alimardani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Farahavar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Najafi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shafiee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanideh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tamaddon</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ahadian</surname><given-names>S.</given-names></name></person-group><part-title>Nanotechnology-based approaches against COVID-19</part-title><source>Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance</source><year>2022</year><publisher-name>Elsevier</publisher-name><fpage>305</fpage><lpage>364</lpage></element-citation></ref><ref id="bib192"><label>186</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Samal</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Mohanty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>S.K.</given-names></name></person-group><article-title>A&#160;review on superhydrophobic polymer nanocoatings: recent development and applications</article-title><source>Ind. Eng. Chem. Res.</source><volume>57</volume><year>2018</year><fpage>2727</fpage><lpage>2745</lpage></element-citation></ref><ref id="bib193"><label>187</label><element-citation publication-type="book" id="sref193"><person-group person-group-type="author"><name name-style="western"><surname>Asmatulu</surname><given-names>R.</given-names></name></person-group><part-title>Nanocoatings for corrosion protection of aerospace alloys</part-title><source>Corrosion Protection and Control Using Nanomaterials</source><year>2012</year><publisher-name>Elsevier</publisher-name><fpage>357</fpage><lpage>374</lpage></element-citation></ref><ref id="bib194"><label>188</label><element-citation publication-type="journal" id="sref194"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>L.C.</given-names></name></person-group><article-title>Copper surfaces in biofilm control</article-title><source>Nanomaterials</source><volume>10</volume><year>2020</year><fpage>2491</fpage><pub-id pub-id-type="pmid">33322518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano10122491</pub-id><pub-id pub-id-type="pmcid">PMC7764739</pub-id></element-citation></ref><ref id="bib195"><label>189</label><element-citation publication-type="journal" id="sref195"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yi-Yi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chun-Yuan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhen-Xing</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name></person-group><article-title>Silver nanoparticles: synthesis, medical applications and biosafety</article-title><source>Theranostics</source><volume>10</volume><year>2020</year><fpage>8996</fpage><pub-id pub-id-type="pmid">32802176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.45413</pub-id><pub-id pub-id-type="pmcid">PMC7415816</pub-id></element-citation></ref><ref id="bib196"><label>190</label><element-citation publication-type="journal" id="sref196"><person-group person-group-type="author"><name name-style="western"><surname>Almanza-Reyes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plascencia-L&#243;pez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alvarado-Vera</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patr&#243;n-Romero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Borrego</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reyes-Escamilla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valencia-Manzo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pestryakov</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: in&#160;vitro and in&#160;vivo</article-title><source>PLoS One</source><volume>16</volume><year>2021</year><object-id pub-id-type="publisher-id">e0256401</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0256401</pub-id><pub-id pub-id-type="pmcid">PMC8375774</pub-id><pub-id pub-id-type="pmid">34411199</pub-id></element-citation></ref><ref id="bib197"><label>191</label><element-citation publication-type="book" id="sref197"><person-group person-group-type="author"><name name-style="western"><surname>Casale</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sabatino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moffa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciccozzi</surname><given-names>M.</given-names></name></person-group><part-title>Could nasal irrigation and oral rinse reduce the risk for COVID-19 infection?</part-title><source>International Journal of Immunopathology and Pharmacology</source><year>2020</year><publisher-name>SAGE Publications Sage UK</publisher-name><publisher-loc>London, England</publisher-loc><object-id pub-id-type="publisher-id">2058738420941757</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2058738420941757</pub-id><pub-id pub-id-type="pmcid">PMC7436790</pub-id><pub-id pub-id-type="pmid">32799596</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability" id="da0010"><title>Data availability</title><p id="p0035">No data was used for the research described in the article.</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0430">The authors thank the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004859</institution-id><institution>Central University of Gujarat</institution></institution-wrap></funding-source> (CUG), Gandhinagar, and the Central Instrumentation Facility (CIF), CUG, for providing necessary facilities and support. Raghu Solanki acknowledges the Council of Scientific and Industrial Research (CSIR) for providing a Senior Research Fellowship (SRF).</p></ack></back></article></pmc-articleset>